{
    "cells": [
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "# Clinical Trial Navigator\n\nThis program is a tool to query the ClinicalTrials.gov database, build a formatted data table of clinical trials based on custom search criteria.  The data table will contain details on clinical trial design, protocol, indication, product, start/completion date, and outcome measures.  Outcome measures are specifically broken out in detail to allow for more in-depth analyses.\n\nUsers can then search across a data table containing all primary and secondary endpoints used in all clinical trials returned in the study data table, to identify how many studies reported a specific endpoint.\n\nThis database file can also be used to conduct detailed analyses, i.e. compare trial duration, sample size, primary / secondary endpoints, and outcome measure performance for all phase 3 trials in a specific indication or drug class."
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "I took a hybrid object-oriented / functional approach for the Clinical Trial Navigator tool.\n\nI designed a Query class to draft a query URL that will be used to search the ClinicalTrials.gov API.  I pre-selected a list of field names I found to be of greatest interest (the API allows up to 25 field values per query), and the full list of field names can be found at https://clinicaltrials.gov/api/info/study_structure. The list of field values included in the query can be modified as needed on an ad-hoc basis.  \n\nThe Query class then converts the JSON query result to a pandas dataframe to allow for easier analysis.\n\nThe Study class represents individual clinical studies, and will be used to extract the various clinical trial criteria (i.e. all primary + secondary endpoints) from the individual studies to allow for more detailed analyses.\n\nI built several functions to clean, format, search and analyze the data returned from each query and study."
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "import pandas as pd\nimport numpy as np\nimport matplotlib.pyplot as plt\nimport seaborn as sns\nimport requests\nimport json\nfrom pandas.io.json import json_normalize # tranform JSON file into a pandas dataframe\nimport time\nfrom textwrap import wrap\n\n#import nltk                                        # previous version of this project tried to leverage the NLTK package, but I decided against it for now\n#from nltk.tokenize import word_tokenize\n\n#nltk.download('punkt')\n    \npd.set_option('display.max_columns', None)\npd.set_option('display.max_rows', None)\npd.set_option('max_colwidth', 100)",
            "execution_count": 1,
            "outputs": []
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "class Query:        # class to create a query from the clinicaltrials API that will house the list of clinical trials returned from the API, with detailed information for each\n    \n    def __init__(self, name = 'Query_1'):\n        self.name = name\n        self.study_tracker = []         # build list that tracks which studies have been built via build_study within the query\n\n    def build_query(self):\n        self.query_terms = input('\\n\\nEnter the search query term: \\n\\n')           # input search terms used to query the clinicaltrials.gov API - tokenize into a list of search terms\n        \n        print('\\n\\nSearch Term: \\n\\n'+self.query_terms+'\\n\\n')\n        \n        query_tokenized = self.query_terms.split()\n        \n        field_values = ['NCTId', 'BriefTitle', 'Condition', 'Phase', 'StudyType',\n                        'EnrollmentCount', 'StartDate', 'PrimaryCompletionDate', 'EligibilityCriteria', 'InterventionName', \n                        'ArmGroupInterventionName', 'ArmGroupDescription', 'InterventionArmGroupLabel', 'OutcomeMeasureType', 'OutcomeMeasureTitle',\n                        'OutcomeMeasureDescription', 'OutcomeMeasureTimeFrame', 'OutcomeMeasurementValue', 'OutcomeMeasureUnitOfMeasure']\n        \n        max_rank = 1000             # max # of items returned by the API query (max for the clinicaltrials.gov API is 1000)\n        \n        \n        url = 'https://clinicaltrials.gov/api/query/study_fields?expr='\n        \n        for i, word in enumerate(query_tokenized):              # build query URL by adding all search terms and field values to the query URL, following the appropriate format\n            if i == 0:\n                url = url + word\n            else:\n                url = url + '+' + word\n            \n        url = url + '&fields='\n        \n        for i, word in enumerate(field_values):\n            if i == 0:\n                url = url + word\n            else:\n                url = url + '%2C' + word\n        \n        url = url + '&min_rnk=1&max_rnk=' + str(max_rank) + '&fmt=json' \n        url = url.strip()\n        self.url = url\n        \n        print('\\n\\nQuerying up to 1,000 trials from clinicaltrials.gov with the following url...\\n\\n'+url+'\\n\\n')\n        \n        return self.url\n        \n    def build_study_table(self, url):\n          \n        ## convert the clinicaltrials.gov JSON response to a pandas dataframe\n        \n        result = requests.get(url).json()\n        result_list = [result for result in result['StudyFieldsResponse']['StudyFields'] if result['OutcomeMeasureType']]     #loop through the list and identify ONLY studies with outcome measures reported \n        df_master = json_normalize(result_list[0])      # initialize dataframe using JSON result\n\n        try:\n            for study in result_list[1:]:        # concatenate each study to the dataframe to generate master dataframe\n                df = json_normalize(study)\n                df_master = pd.concat([df_master, df], axis=0, ignore_index=True)\n        except:\n            pass\n                                                                    # extract list entries, reformat data in these columns as strings\n        try:                                            \n            df_master['NCTId'] = [df_master['NCTId'][i][0] for i in range(len(df_master['NCTId'])) if len(df_master['NCTId'][i]) > 0]\n        except:\n            pass        \n        try:\n            df_master['BriefTitle'] = [df_master['BriefTitle'][i][0] for i in range(len(df_master['BriefTitle'])) if len(df_master['BriefTitle'][i]) > 0]\n        except:\n            pass       \n        try:\n            df_master['Condition'] = [df_master['Condition'][i][0] for i in range(len(df_master['Condition'])) if len(df_master['Condition'][i]) > 0]\n        except:\n            pass\n        try:\n            df_master['StudyType'] = [df_master['StudyType'][i][0] for i in range(len(df_master['StudyType'])) if len(df_master['StudyType'][i]) > 0]\n        except:\n            pass\n        \n        \n        for i in range(len(df_master['Phase'])):                    # extract clinical trial phase(s)\n            if df_master['Phase'][i]:\n                if len(df_master['Phase'][i]) > 1:\n                    df_master['Phase'][i] = df_master['Phase'][i][0] + ', ' + df_master['Phase'][i][1]\n                else:\n                    df_master['Phase'][i] = df_master['Phase'][i][0]\n            else:\n                df_master['Phase'][i] = 'Unknown'\n        \n        \n        try:\n            df_master['EnrollmentCount'] = [df_master['EnrollmentCount'][i][0] for i in range(len(df_master['EnrollmentCount'])) if len(df_master['EnrollmentCount'][i]) > 0]\n        except:\n            pass\n        try:\n            df_master['StartDate'] = [df_master['StartDate'][i][0] for i in range(len(df_master['StartDate'])) if len(df_master['StartDate'][i]) > 0]\n        except:\n            pass\n        try:\n            df_master['PrimaryCompletionDate'] = [df_master['PrimaryCompletionDate'][i][0] for i in range(len(df_master['PrimaryCompletionDate'])) if len(df_master['PrimaryCompletionDate'][i]) > 0]\n        except:\n            pass\n        try:\n            df_master['EligibilityCriteria'] = [df_master['EligibilityCriteria'][i][0] for i in range(len(df_master['EligibilityCriteria'])) if len(df_master['EligibilityCriteria'][i]) > 0]\n        except:\n            pass\n        \n        #df_master['StartDate'] = pd.to_datetime(df_master['StartDate'])\n        #df_master['PrimaryCompletionDate'] = pd.to_datetime(df_master['PrimaryCompletionDate'])            # future version of this project will convert starting / ending date to datetime format, to calculate/analyze trial duration\n        \n        self.df_master = df_master\n        \n        return self.df_master\n    \n    def build_outcome_table(self):\n        \n        # initialize an outcomes_df from the first study within the query study table\n        \n        query_df_master = self.get_df_master()\n        query_df_master = query_df_master[query_df_master['Phase'].str.match('.*3.*', na=False)].reset_index()          # filter ONLY phase 3 studies, which represent pivotal efficacy/safety trials used by the FDA when evaluating a new product \n        study_1 = Study(self, query_df_master['NCTId'][0])\n        \n        outcomes_df = study_1.extract_outcomes()\n        \n        study_x = Study(self, query_df_master['NCTId'][1])\n        df = study_x.extract_outcomes()\n        outcomes_df = pd.concat([outcomes_df, df], axis=0, ignore_index=False)\n        \n        for i in range(1, len(query_df_master)):                         # concatenate each study to the dataframe to generate master dataframe\n            study_x = Study(self, query_df_master['NCTId'][i])\n            df = study_x.extract_outcomes()\n            outcomes_df = pd.concat([outcomes_df, df], axis=0, ignore_index=False)\n        \n        outcomes_df = outcomes_df.reset_index().drop(columns='index')\n        \n        return outcomes_df\n\n    \n    def get_url(self):\n        return self.url\n\n    def get_study_tracker(self):\n        return self.study_tracker\n    \n    def get_df_master(self):\n        if len(self.df_master)>0:\n            return self.df_master\n        else:\n            return 'No df_master exists!'",
            "execution_count": 2,
            "outputs": []
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "class Study:\n    \n    def __init__(self, query, nct_id):                  # all studies are initialized within a query, and are identified via their unique NCT ID (created by clinicaltrials.gov)s\n        \n        self.nct_id = nct_id\n        self.entry = query.get_df_master()[query.get_df_master()['NCTId']==nct_id].reset_index().drop(columns='index')      #build a unique df entry for this NCT ID\n        self.df_outcomes = pd.DataFrame(columns=self.entry.columns)\n        \n        try:                            # identify the number of outcome measure values reported per outcome measure (i.e., measure at baseline, change at week N, P value, etc.)\n            self.measures_per_outcome = len(self.entry['OutcomeMeasurementValue'][0])//len(self.entry['OutcomeMeasureTitle'][0])\n        except:\n            self.measures_per_outcome = 1\n        \n        if self.nct_id not in query.study_tracker:              #add the study to the query's study tracker\n            query.study_tracker.append(self.nct_id)\n        \n    def get_entry(self):\n        return self.entry\n    \n    def get_indication(self):\n        return [item for item in self.entry['Condition']][0]     # returns the first list item within the list of indications\n\n    def extract_outcomes(self):            #iterate thru all outcome measures, create a dataframe with all required info\n        \n        try:\n            self.df_outcomes = self.df_outcomes.drop(columns=['Rank', 'Condition', 'StudyType', 'EnrollmentCount', 'StartDate', 'PrimaryCompletionDate', 'EligibilityCriteria', 'ArmGroupDescription'])\n        except:\n            pass\n        \n        for i, item in enumerate(self.entry['OutcomeMeasureType']):\n                \n            try:\n                self.df_outcomes['OutcomeMeasureType'] = [item for item in self.entry['OutcomeMeasureType']][0]\n            except:\n                pass\n            try:\n                self.df_outcomes['OutcomeMeasureTitle'] = [item for item in self.entry['OutcomeMeasureTitle']][0]\n            except:\n                pass\n            try:\n                self.df_outcomes['OutcomeMeasureDescription'] = [item for item in self.entry['OutcomeMeasureDescription']][0]\n            except:\n                pass\n            try:\n                self.df_outcomes['OutcomeMeasureTimeFrame'] = [item for item in self.entry['OutcomeMeasureTimeFrame']][0]\n            except:\n                pass\n            try:\n                self.df_outcomes['OutcomeMeasureUnitOfMeasure'] = [item for item in self.entry['OutcomeMeasureUnitOfMeasure']][0]\n            except:\n                pass\n\n        beginning = 0\n        increment = self.measures_per_outcome               # maps correct number of outcome measures reported in the study, as multiple performance values may pertain to each endpoint (i.e. value for each intervention arm + placebo)\n       \n        for i in range(len(self.df_outcomes)):\n            try:\n                self.df_outcomes['OutcomeMeasurementValue'][i] = self.entry['OutcomeMeasurementValue'][0][beginning:beginning+increment]\n                beginning += increment\n            except:\n                pass\n            try:\n                self.df_outcomes['InterventionArmGroupLabel'][i] = self.entry['InterventionArmGroupLabel'][0]\n            except:\n                pass\n            try:\n                self.df_outcomes['InterventionName'][i] = self.entry['InterventionName'][0]\n            except:\n                pass\n            try:\n                self.df_outcomes['ArmGroupInterventionName'][i] = self.entry['ArmGroupInterventionName'][0]\n            except:\n                pass\n        \n        self.df_outcomes['NCTId'] = [item for item in self.entry['NCTId']][0]\n        self.df_outcomes['Phase'] = [item for item in self.entry['Phase']][0]\n        self.df_outcomes['BriefTitle'] = [item for item in self.entry['BriefTitle']][0]\n        \n        return self.df_outcomes",
            "execution_count": 3,
            "outputs": []
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "def outcome_track(outcome_list, track_dict):  # function to build a dictionary counter object that tracks the count of each endpoint within the outcome list\n                                              ## can be used to plot the top N outcome measures used in clinical studies for a certain indication\n    \n    for outcome in outcome_list:\n        if outcome in track_dict.keys():\n            track_dict[outcome] += 1\n        else:\n            track_dict[outcome] = 1\n\ndef plot_outcomes(outcome_df, query):                   # function to plot the top 10 outcome measures used in the outcomes dataframe provided as input\n    \n    n_endpoints = 10                                      # how many endpoints will be plotted (top N endpoints)\n    fig = plt.figure(figsize=[36, 10]).tight_layout(w_pad=2.0, h_pad = 2.0)\n    ax = sns.barplot(data=outcome_df.head(n_endpoints), x='index', y='Frequency', estimator=sum, ci=None)\n\n    for p in ax.patches:\n        ax.text(x = p.get_x()+(p.get_width()/2),y = p.get_height()+0.05,s = '{}'.format(p.get_height(),ha = 'center'))\n\n    labels = []\n    \n    for label in ax.get_xticklabels():\n        labels.append(label.get_text())\n\n    labels = [ '\\n'.join(wrap(l, 20)) for l in labels]              # wrap label text to improve presentability (many endpoints are long text blocks)\n\n    ax.set_title('Top 10 Most Common Primary + Secondary Outcome Measures Reported in {} Clinical Trials'.format(query.query_terms.title()), fontsize=14)\n    ax.set_xticklabels(labels, fontsize=13, va='top', ha='center')\n    ax.set_xlabel('Outcome Measure', fontsize=14)\n    plt.show()\n\n    \ndef tokenize_column(outcome_table, column_name, new_column_name):           # function to convert the text contained in one column into a tokenized, lowercase list of terms (stripped of whitespace and parentheses characters)\n                                                                            ## in a new column\n    outcome_table[new_column_name] = outcome_table[column_name].str.split()\n    \n    for i in range(len(outcome_table[new_column_name])):\n        for j in range(len(outcome_table[new_column_name][i])):\n            outcome_table[new_column_name][i][j] = outcome_table[new_column_name][i][j].lower().strip(' ()')\n    \ndef search_outcomes(outcome_table, col_to_search):                           # function to search an outcomes table and determine how many times ALL the terms in a keyword search appear in the tokenized lise \n    \n    global search_term \n    search_term = input('Enter your search term here: \\n')\n    tokenized = search_term.split()\n    tokenized_clean = [word.lower().strip() for word in tokenized]\n\n    match_tracker = []\n\n    for i in range(len(outcome_table)):\n        matches=0    \n        for word in tokenized_clean:\n            if word in outcome_table[col_to_search][i]:\n                matches +=1\n        if matches == len(tokenized_clean):\n            match_tracker.append(i)\n    \n    # create empty dataframe with identical columns to outcomes df; iterate through index values in match_tracker; append outcomes_df.iloc[index]\n\n    outcome_table_filtered = pd.DataFrame(columns=outcome_table.columns)\n\n    for ind in match_tracker:\n        outcome_table_filtered.loc[ind] = outcome_table.loc[ind] \n            \n    outcome_table_filtered = outcome_table_filtered.reset_index()\n    outcome_table_filtered\n    \n    print('\\nSearching outcomes that contain the following key terms:\\n')\n    print(tokenized_clean)\n\n    return outcome_table_filtered\n\ndef plot_outcome_search(outcome_table_filtered):\n    \n    outcome_plot_dict = {}\n    outcome_plot_dict[search_term] = outcome_table_filtered.shape[0]\n\n    outcome_plot_df = pd.Series(outcome_plot_dict).to_frame('Frequency').reset_index().sort_values(by='Frequency', ascending=False).reset_index()\n\n    fig = plt.figure(figsize=[14,6]).tight_layout(pad=8.0)\n    ax = sns.barplot(data=outcome_plot_df, x='index', y='Frequency', estimator=sum)\n\n    for p in ax.patches:\n            ax.text(x = p.get_x()+(p.get_width()/2),y = p.get_height()*1.01,s = '{}'.format(p.get_height(),ha = 'center'), fontsize=14)\n\n    ax.set_title('Number of Endpoints Returned from Search')\n    ax.set_xlabel('search term')",
            "execution_count": 4,
            "outputs": []
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "# Below I will demonstrate how this tool works through a few use case examples.\n\n\n\n\nThe first example will involve a query for clinical trials for eosinophilic asthma, an uncommon, severe type of asthma involving increased levels of eosinophils in the blood."
        },
        {
            "metadata": {
                "scrolled": true
            },
            "cell_type": "code",
            "source": "asthma = Query()\nasthma.build_query()",
            "execution_count": 5,
            "outputs": [
                {
                    "output_type": "stream",
                    "name": "stdout",
                    "text": "\n\nEnter the search query term: \n\neosinophilic asthma\n\n\nSearch Term: \n\neosinophilic asthma\n\n\n\n\nQuerying up to 1,000 trials from clinicaltrials.gov with the following url...\n\nhttps://clinicaltrials.gov/api/query/study_fields?expr=eosinophilic+asthma&fields=NCTId%2CBriefTitle%2CCondition%2CPhase%2CStudyType%2CEnrollmentCount%2CStartDate%2CPrimaryCompletionDate%2CEligibilityCriteria%2CInterventionName%2CArmGroupInterventionName%2CArmGroupDescription%2CInterventionArmGroupLabel%2COutcomeMeasureType%2COutcomeMeasureTitle%2COutcomeMeasureDescription%2COutcomeMeasureTimeFrame%2COutcomeMeasurementValue%2COutcomeMeasureUnitOfMeasure&min_rnk=1&max_rnk=1000&fmt=json\n\n\n"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 5,
                    "data": {
                        "text/plain": "'https://clinicaltrials.gov/api/query/study_fields?expr=eosinophilic+asthma&fields=NCTId%2CBriefTitle%2CCondition%2CPhase%2CStudyType%2CEnrollmentCount%2CStartDate%2CPrimaryCompletionDate%2CEligibilityCriteria%2CInterventionName%2CArmGroupInterventionName%2CArmGroupDescription%2CInterventionArmGroupLabel%2COutcomeMeasureType%2COutcomeMeasureTitle%2COutcomeMeasureDescription%2COutcomeMeasureTimeFrame%2COutcomeMeasurementValue%2COutcomeMeasureUnitOfMeasure&min_rnk=1&max_rnk=1000&fmt=json'"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "### I now have my query URL written, and can generate a table of all clinical trials returned from the query (max of 1,000 trials, per clinicaltrials.gov API limit) using the Query class's build_study_table function."
        },
        {
            "metadata": {
                "scrolled": true
            },
            "cell_type": "code",
            "source": "asthma_study_table = asthma.build_study_table(asthma.get_url())\nasthma_study_table",
            "execution_count": 6,
            "outputs": [
                {
                    "output_type": "stream",
                    "text": "/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:52: FutureWarning: pandas.io.json.json_normalize is deprecated, use pandas.json_normalize instead\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:56: FutureWarning: pandas.io.json.json_normalize is deprecated, use pandas.json_normalize instead\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:84: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:86: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:82: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
                    "name": "stderr"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 6,
                    "data": {
                        "text/plain": "    Rank        NCTId  \\\n0      4  NCT01285323   \n1      6  NCT01287039   \n2      8  NCT01270464   \n3      9  NCT01290887   \n4     13  NCT02654145   \n5     22  NCT02555371   \n6     24  NCT02281318   \n7     27  NCT01312961   \n8     28  NCT03052725   \n9     45  NCT03021304   \n10    46  NCT03099096   \n11    47  NCT02377427   \n12    51  NCT01508936   \n13    58  NCT02937168   \n14    62  NCT02135692   \n15    75  NCT02836496   \n16    95  NCT02869438   \n17    98  NCT00283504   \n18   102  NCT02898662   \n19   106  NCT03299686   \n20   111  NCT01238861   \n21   112  NCT00587288   \n22   115  NCT00802438   \n23   126  NCT00123630   \n24   128  NCT03170271   \n25   129  NCT00712335   \n26   134  NCT01842607   \n27   136  NCT01691508   \n28   139  NCT02392481   \n29   147  NCT01821898   \n30   151  NCT01458418   \n31   168  NCT02104505   \n\n                                                                                             BriefTitle  \\\n0        A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n1   A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...   \n2   A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...   \n3   Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/k...   \n4                         Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients   \n5         Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients   \n6   Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinoph...   \n7   Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe E...   \n8           A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma   \n9                                                     Study of Mepolizumab Safety Syringe in Asthmatics   \n10                                                      Study of Mepolizumab Autoinjector in Asthmatics   \n11         Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children   \n12  Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...   \n13  An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inf...   \n14     A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects   \n15    Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)   \n16  A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...   \n17  A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic an...   \n18                                                                                   AZD1419 Ph2a Study   \n19  Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Sever...   \n20             Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma   \n21                            Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma   \n22                                                     Eosinophilic Airway Inflammation and Mepolizumab   \n23                           A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab   \n24  A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontroll...   \n25                                                    The Effects of Montelukast on Smokers With Asthma   \n26                           A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects   \n27                          Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma   \n28                                                                               Asthma Biomarker Study   \n29                                           Eosinophilic Esophagitis Clinical Therapy Comparison Trial   \n30               A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children   \n31                       Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS   \n\n                     Condition             Phase       StudyType  \\\n0          Eosinophilic Asthma           Phase 3  Interventional   \n1          Eosinophilic Asthma           Phase 3  Interventional   \n2          Eosinophilic Asthma           Phase 3  Interventional   \n3          Eosinophilic Asthma           Phase 3  Interventional   \n4                       Asthma           Phase 4  Interventional   \n5                       Asthma           Phase 3  Interventional   \n6                       Asthma           Phase 3  Interventional   \n7                       Asthma           Phase 2  Interventional   \n8          Eosinophils, Asthma           Phase 3  Interventional   \n9                       Asthma           Phase 3  Interventional   \n10                      Asthma           Phase 3  Interventional   \n11                      Asthma           Phase 2  Interventional   \n12         Eosinophilic Asthma           Phase 3  Interventional   \n13                      Asthma           Phase 4  Interventional   \n14                      Asthma           Phase 3  Interventional   \n15  Hypereosinophilic Syndrome           Phase 3  Interventional   \n16                      Asthma           Phase 3  Interventional   \n17             ALLERGIC ASTHMA           Phase 4  Interventional   \n18                      Asthma           Phase 2  Interventional   \n19                      Asthma           Phase 2  Interventional   \n20                      Asthma           Phase 2  Interventional   \n21                      Asthma           Phase 2  Interventional   \n22                      Asthma    Not Applicable  Interventional   \n23                 Esophagitis           Phase 2  Interventional   \n24                      Asthma           Phase 3  Interventional   \n25           Asthmatic Smokers           Phase 4  Interventional   \n26                      Asthma           Phase 3  Interventional   \n27                      Asthma           Phase 3  Interventional   \n28                      Asthma           Unknown   Observational   \n29    Eosinophilic Esophagitis           Phase 2  Interventional   \n30    Eosinophilic Esophagitis    Not Applicable  Interventional   \n31       Mild, Allergic Asthma  Phase 1, Phase 2  Interventional   \n\n   EnrollmentCount          StartDate PrimaryCompletionDate  \\\n0              464         March 2011            April 2014   \n1              489         April 2011         December 2013   \n2              315      February 2011        September 2013   \n3             1052          June 2011          January 2015   \n4              145     March 17, 2016          May 31, 2017   \n5              306    January 7, 2016         July 24, 2019   \n6              556  December 11, 2014         June 10, 2016   \n7              104         March 2011          October 2012   \n8              391     March 10, 2017     February 22, 2018   \n9               56   February 1, 2017        August 8, 2017   \n10             159        May 4, 2017     November 30, 2017   \n11              36    August 25, 2015      December 7, 2016   \n12             511      February 2012           August 2013   \n13               5        May 8, 2017          May 24, 2017   \n14             339       May 29, 2014       October 5, 2017   \n15             108      March 7, 2017        August 8, 2019   \n16             233   November 9, 2016        August 1, 2018   \n17              13       January 2006          January 2009   \n18              81   October 12, 2016    September 25, 2018   \n19             118   November 6, 2017         April 8, 2019   \n20             964      December 2010            March 2013   \n21             106         April 2008            March 2010   \n22              38       June 1, 2008         March 1, 2013   \n23              30      November 2005          January 2010   \n24             660       July 7, 2017    September 25, 2019   \n25             105      February 2007              May 2011   \n26             651       May 27, 2013        March 13, 2015   \n27             135       October 2012         December 2013   \n28              69      July 16, 2015       January 3, 2017   \n29               3       July 9, 2013    September 24, 2018   \n30               4      December 2011         February 2015   \n31              23      November 2015        September 2016   \n\n                                                                                    EligibilityCriteria  \\\n0   Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...   \n1   Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...   \n2   Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...   \n3   Inclusion Criteria:\\n\\nWritten informed consent is obtained.\\nPatient must have completed treatm...   \n4   Inclusion Criteria:\\n\\nAt least 12 years of age at the time of signing the informed consent. For...   \n5   Inclusion Criteria:\\n\\nInformed Consent: Prior to commencing any study related activities, subje...   \n6   Inclusion Criteria:\\n\\nAge: At least 12 years of age at the time of signing the informed consent...   \n7   Inclusion criteria:\\n\\nMedical diagnosis of persistent asthma for at least 12 months whose:\\n\\na...   \n8   Inclusion Criteria:\\n\\n\u2022 Patient with eosinophilic asthma who completed the treatment period of ...   \n9   Inclusion Criteria:\\n\\nAge: At least 12 years of age inclusive, at the time of signing the infor...   \n10  Inclusion Criteria:\\n\\nAge: At least 12 years of age inclusive, at the time of signing the infor...   \n11  Inclusion Criteria:\\n\\nBetween 6 and 11 years of age inclusive, at the time of screening.\\nDiagn...   \n12  Inclusion criteria:\\n\\nPatients are included in the study if all of the following criteria are m...   \n13  Inclusion Criteria:\\n\\nMale or female, 18 through 50 years of age.\\nFemales that are either surg...   \n14  Inclusion Criteria:\\n\\nInformed Consent: Prior to commencing any study related activities, subje...   \n15  Inclusion Criteria:\\n\\nCapable of giving signed informed consent/assent which includes complianc...   \n16  Inclusion criteria\\n\\nWritten informed consent for study participation must be obtained prior to...   \n17  Inclusion Criteria:\\n\\nModerate to severe allergic asthma, uncontrolled on conventional therapy\\...   \n18  Inclusion Criteria:\\n\\nMale and female patients 18 years and above\\nPhysician-diagnosed asthma r...   \n19  Inclusion Criteria:\\n\\nPatients with a physician-diagnosed history of moderate to severe asthma ...   \n20  Inclusion Criteria:\\n\\nAge 18 through 75 years at the time of screening\\nAdequate contraception ...   \n21  Inclusion Criteria:\\n\\nwritten informed consent\\nmale or female subjects aged \u2265 18 to 75 years a...   \n22  Inclusion Criteria:\\n\\nMales or females age 18 to 50 yrs,\\nHistory of asthma based upon presence...   \n23  Inclusion Criteria:\\n\\nMale or female subjects aged 12-60 years of age with EE as defined above\\...   \n24  Inclusion Criteria:\\n\\nFemale and male patients aged 18 to 75 years inclusively at the time of V...   \n25  Inclusion Criteria:\\n\\nAsthmatics:\\n\\nclinical history of asthma for at least 1 year\\nwith evide...   \n26  Inclusion Criteria:\\n\\nFrench subjects: In France, a subject will be eligible for inclusion in t...   \n27  Inclusion Criteria:\\n\\nInformed Consent and Study Compliance: Subjects must be able to give writ...   \n28  Inclusion criteria:\\n\\nBody mass index (BMI) >=18 and <= 40 Non-smokers or ex-smokers with a cig...   \n29  Inclusion Criteria\\n\\nSigned written informed consent and assent if applicable prior to performi...   \n30  Inclusion Criteria:\\n\\nMales and females aged 2-17\\nPresence of more than 15 eosinophils per hpf...   \n31  Inclusion Criteria:\\n\\nAge 18-50 of both genders\\nNegative pregnancy test for females who are no...   \n\n                                                                                       InterventionName  \\\n0                                                                                 [Reslizumab, Placebo]   \n1                                                                                 [Reslizumab, Placebo]   \n2                                                                                 [Reslizumab, Placebo]   \n3                                                                                          [Reslizumab]   \n4                                         [Mepolizumab 100mg SC, Albuterol/salbutamol MDIs, Omalizumab]   \n5                                                                          [Mepolizumab 100mg, Placebo]   \n6                                                                           [Mepolizumab, Placebo, SOC]   \n7   [Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone mon...   \n8                                                                                          [reslizumab]   \n9                                                                                         [Mepolizumab]   \n10                                                                                        [Mepolizumab]   \n11                                                                                        [Mepolizumab]   \n12                                                                                [Reslizumab, Placebo]   \n13                                                    [Reslizumab, Fludeoxyglucose F 18 (FDG), Placebo]   \n14                                                                                   [Mepolizumab, SOC]   \n15  [Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or pre...   \n16                                                                              [Benralizumab, Placebo]   \n17                                                                          [ANTI-IGE THERAPY (XOLAIR)]   \n18                                                                                   [AZD1419, Placebo]   \n19                                                                          [CJM112, Placebo to CJM112]   \n20                                [Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg, Placebo]   \n21                                                                                 [Reslizumab, Saline]   \n22                                                                                        [mepolizumab]   \n23                                                                                [omalizumab, Placebo]   \n24                                                                   [Benralizumab (Medi-563), Placebo]   \n25                                                    [Fluticasone Propionate, Montelukast, Salmeterol]   \n26                                                                                        [Mepolizumab]   \n27                                                [Mepolizumab, Placebo, OCS (prednisone/prednisolone)]   \n28                                                                                  [Biofluid sampling]   \n29                                                                  [Oral Budesonide, Elimination diet]   \n30                                                             [Montelukast, placebo, 5 mg Montelukast]   \n31                                                         [Gamma Tocopherol 700 mg capsules,, Placebo]   \n\n                                                                               ArmGroupInterventionName  \\\n0                                                                     [Drug: Placebo, Drug: Reslizumab]   \n1                                                                     [Drug: Placebo, Drug: Reslizumab]   \n2                                                   [Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab]   \n3                                                                                    [Drug: Reslizumab]   \n4                       [Drug: Mepolizumab 100mg SC, Drug: Albuterol/salbutamol MDIs, Drug: Omalizumab]   \n5                         [Biological: Mepolizumab 100mg, Biological: Mepolizumab 100mg, Drug: Placebo]   \n6                                        [Biological: Mepolizumab, Drug: SOC, Drug: Placebo, Drug: SOC]   \n7   [Drug: Placebo (for Dupilumab), Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticas...   \n8                                                                                    [Drug: reslizumab]   \n9                                                                                   [Drug: Mepolizumab]   \n10                                                                                  [Drug: Mepolizumab]   \n11                                                               [Drug: Mepolizumab, Drug: Mepolizumab]   \n12                                                                    [Drug: Placebo, Drug: Reslizumab]   \n13  [Drug: Fludeoxyglucose F 18 (FDG), Drug: Reslizumab, Drug: Fludeoxyglucose F 18 (FDG), Drug: Flu...   \n14                                                                 [Biological: Mepolizumab, Drug: SOC]   \n15  [Drug: Mepolizumab 300 mg, Drug: Active OCS capsules (5 mg prednisolone or prednisone), Drug: Pl...   \n16                                                                 [Drug: Benralizumab, Other: Placebo]   \n17                                                                    [Drug: ANTI-IGE THERAPY (XOLAIR)]   \n18                                                                       [Drug: AZD1419, Drug: Placebo]   \n19                                                             [Drug: CJM112, Other: Placebo to CJM112]   \n20  [Other: Placebo, Biological: Benralizumab 2 mg, Biological: Benralizumab 20 mg, Biological: Benr...   \n21                                                              [Biological: Reslizumab, Other: Saline]   \n22                                                                            [Biological: mepolizumab]   \n23                                                                    [Drug: Placebo, Drug: omalizumab]   \n24                                                       [Drug: Benralizumab (Medi-563), Drug: Placebo]   \n25  [Drug: Fluticasone Propionate, Drug: Salmeterol, Drug: Montelukast, Drug: Fluticasone Propionate...   \n26                                                                            [Biological: Mepolizumab]   \n27  [Drug: Mepolizumab, Drug: OCS (prednisone/prednisolone), Drug: Placebo, Drug: OCS (prednisone/pr...   \n28                                                                       [Procedure: Biofluid sampling]   \n29                                                     [Drug: Oral Budesonide, Other: Elimination diet]   \n30                                          [Drug: Montelukast, Drug: 5 mg Montelukast, Other: placebo]   \n31                                             [Drug: Gamma Tocopherol 700 mg capsules,, Drug: Placebo]   \n\n                                                                                    ArmGroupDescription  \\\n0   [Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses., Res...   \n1   [Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses., Res...   \n2   [Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses., 0.3 mg/kg,...   \n3   [Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 mon...   \n4   [Subjects with severe eosinophilic asthma who are receiving omalizumab will enter a run-in perio...   \n5   [There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up t...   \n6   [Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh ev...   \n7   [Placebo (for Dupilumab) subcutaneous (SC) injection once weekly (qw) for 12 weeks added to back...   \n8   [Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or upp...   \n9   [Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, sub...   \n10  [Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the...   \n11  [Participants with bodyweight < 40 kg will receive 0.4 milliliter (mL) of reconstituted mepolizu...   \n12  [Placebo intravenous injection every 4 weeks for a total of 4 doses., Reslizumab intravenous inj...   \n13  [Healthy participants will have 2 PET/CT scan in Part 1: within 7 days of eligibility being conf...   \n14  [All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approxi...   \n15  [Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 w...   \n16                      [Benralizumab administered subcutaneously, Placebo administered subcutaneously]   \n17                                                                                [One arm:active drug]   \n18        [Dose adaption of AZD1419, 4 mg or 8 mg or 1 mg based on occurence of AE's, Matching placebo]   \n19                                                                           [Study treatment, Placebo]   \n20  [EOS+ (defined as ELEN Index [proprietary mathematical algorithm to predict sputum eosinophil's ...   \n21  [Reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles, S...   \n22                                                    [up to 3 monthly doses of 750mg i.v. mepolizumab]   \n23                                                                        [placebo group, Xolair group]   \n24  [Benralizumab (Medi563) Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 da...   \n25  [Asthmatic smokers treated with combination therapy:\\n\\nFluticasone propionate dosage - DPI 250 ...   \n26  [Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously ...   \n27  [Mepolizumab 100 mg subcutaneous once every 4 weeks upto Week 20, Placebo subcutaneous once ever...   \n28                                                                                                   []   \n29                                                                  [Oral Budesonide, Elimination diet]   \n30  [Subjects will receive two 5mg tablets of Montelukast/day., Subjects will receive one 5mg tablet...   \n31                                                [Gamma Tocopherol supplement, Safflower oil capsules]   \n\n                                                                              InterventionArmGroupLabel  \\\n0                                                                       [Reslizumab 3.0 mg/kg, Placebo]   \n1                                                                       [Reslizumab 3.0 mg/kg, Placebo]   \n2                                             [Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo]   \n3                                                                                [Reslizumab 3.0 mg/kg]   \n4   [Omalizumab switch to mepolizumab 100mg SC every 4 weeks, Omalizumab switch to mepolizumab 100mg...   \n5                                                    [Arm Mepolizumab 100 mg, Arm Placebo, Arm Placebo]   \n6                                              [Mepolizumab SC, Placebo SC, Mepolizumab SC, Placebo SC]   \n7   [Dupilumab 300 mg qw, Placebo (for Dupilumab), Dupilumab 300 mg qw, Placebo (for Dupilumab), Dup...   \n8                                                                                   [reslizumab 110 mg]   \n9                                             [Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe]   \n10                                              [Mepolizumab SC 100 mg/milliliter (mL) in autoinjector]   \n11                              [Mepolizumab 100 mg in Part A and B, Mepolizumab 40 mg in Part A and B]   \n12                                                                      [Reslizumab 3.0 mg/kg, Placebo]   \n13      [Part 2: Reslizumab, Part 1: PET/CT Scan, Part 2: Placebo, Part 2: Reslizumab, Part 2: Placebo]   \n14                                                             [Mepolizumab 100 mg, Mepolizumab 100 mg]   \n15                                   [Mepolizumab, Placebo, Mepolizumab, Placebo, Mepolizumab, Placebo]   \n16                                                                      [Benralizumab arm, Placebo arm]   \n17                                                           [all patients received Xolair/active drug]   \n18                                                                                   [AZD1419, Placebo]   \n19                                                                          [CJM112, Placebo to CJM112]   \n20  [EOS+ Benralizumab (2 mg), EOS+ Benralizumab (20 mg), EOS+ Benralizumab (100 mg), EOS- Benralizu...   \n21                                                                        [Reslizumab 3 mg/kg, Placebo]   \n22                                                                                        [Mepolizumab]   \n23                                                                                [omalizumab, placebo]   \n24                                                                   [Benralizumab (Medi-563), Placebo]   \n25                                                                                   [1, 3, 2, 4, 1, 3]   \n26                                                                                    [Mepolizumab Arm]   \n27                                                         [Mepolizumab, Placebo, Mepolizumab, Placebo]   \n28                                                                                   [Healthy subjects]   \n29                             [Positive for food allergy: Group A, Positive for food allergy: Group B]   \n30                                                [Montelukast 10 mg/day, placebo, Montelukast 5mg/day]   \n31                                                    [700 mg Gamma Tocopherol daily x 14days, Placebo]   \n\n                                                                                     OutcomeMeasureType  \\\n0   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n1   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n2   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n3   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Primary, Secondary, Se...   \n4                                                            [Primary, Secondary, Secondary, Secondary]   \n5                                                            [Primary, Secondary, Secondary, Secondary]   \n6                                                            [Primary, Secondary, Secondary, Secondary]   \n7   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n8   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n9                                                                                  [Primary, Secondary]   \n10                                                             [Primary, Primary, Secondary, Secondary]   \n11  [Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Prima...   \n12  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n13          [Primary, Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n14  [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n15                                                [Primary, Secondary, Secondary, Secondary, Secondary]   \n16  [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n17                                                                      [Primary, Secondary, Secondary]   \n18    [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n19                                     [Primary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n20  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n21                          [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n22                                                                                 [Primary, Secondary]   \n23                                                                                            [Primary]   \n24  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n25                          [Secondary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n26  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n27                                                [Primary, Secondary, Secondary, Secondary, Secondary]   \n28                                                             [Primary, Primary, Secondary, Secondary]   \n29                                                           [Primary, Secondary, Secondary, Secondary]   \n30                                                                                            [Primary]   \n31                                                           [Primary, Secondary, Secondary, Secondary]   \n\n                                                                                    OutcomeMeasureTitle  \\\n0   [Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment, Change From Ba...   \n1   [Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment, Change From Ba...   \n2   [Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed M...   \n3   [Participants With Treatment-Emergent Adverse Events, Participants With Treatment-Emergent Poten...   \n4   [Mean Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 32, Mean Chan...   \n5   [Percentage of Participants With First Clinically Significant Exacerbation in Part C, Ratio to B...   \n6   [Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 2...   \n7   [Percentage of Participants With Asthma Exacerbation, Time to First Asthma Exacerbation: Kaplan-...   \n8   [Participants With Treatment-Emergent Adverse Events (TEAEs), Participants With Potentially Clin...   \n9   [Percentage of Participants With Successful Self-administration of Their Observed Third Dose at ...   \n10  [Percentage of Participants With Successful Self-administration of Their Observed Third Dose at ...   \n11  [Maximum Plasma Concentration (Cmax) of Mepolizumab for Part A, Area Under Concentration Time Cu...   \n12  [Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis...   \n13  [Part 1: Average Global Lung Glycolysis (GLG) at Baseline (Day 1), Part 1: Average Global Lung G...   \n14  [Annualized Rate of On-treatment Exacerbations Per Year, Number of Participants With Any On-trea...   \n15  [Percentage of Participants Who Experienced an HES Flare or Who Withdrew From the Study During t...   \n16  [Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in ...   \n17  [Number of Participants With Change in Sputum Markers by End of Study, Number of Participants Wi...   \n18  [Number of Participants With Events for Time to Loss of Asthma Control (LOAC) up to Week 52 - Co...   \n19  [Change From Baseline in Forced Expiratory Volume in One Second (FEV1), Change From Baseline in ...   \n20  [Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants, Dose Resp...   \n21  [Mean Change From Baseline to End of Therapy in Asthma Control Questionnaire (ACQ) Score, Percen...   \n22  [The Primary Endpoint of the Study is the Percent of Eosinophils in the Bronchoalveolar Lavage F...   \n23  [Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and ...   \n24  [Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24), Change From ...   \n25  [Sputum Eosinophil Percentages, Sputum Neutrophil Percentages, Sputum IL-8 Levels, Sputum GM-CSF...   \n26  [Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunog...   \n27  [Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroi...   \n28  [Level of Tumour Necrosis Factor-alpha (TNF-\u03b1) in Blood at Baseline (Visit 1), Level of Interleu...   \n29  [Peak Number of Eosinophils/High Powered Field, Quality of Life Survey Score, Symptom Score, Exp...   \n30                                                                                   [Eosinophil Count]   \n31  [Comparison of Change in Sputum Percent Neutrophils (PMN)s Following Inhaled Clinical Center Ref...   \n\n                                                                              OutcomeMeasureDescription  \\\n0   [An exacerbation event was considered a CAE if the patient met either or both of the criteria li...   \n1   [An exacerbation event was considered a CAE if the patient met either or both of the criteria li...   \n2   [FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fr...   \n3   [An adverse event was defined in the protocol as any untoward medical occurrence that develops o...   \n4   [The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma co...   \n5   [Clinically significant exacerbation was defined as worsening of asthma which requires use of sy...   \n6   [SGRQ consisted of 50 questions (scored from 0 to 100 where 0 indicates best and 100 indicates w...   \n7   [An asthma exacerbation was defined as the occurrence of any of the following: \u226530% reduction fr...   \n8   [An adverse event is any untoward medical occurrence, regardless of whether it has a causal rela...   \n9   [During the clinic visits the Investigator or designee evaluated if the participants were able t...   \n10  [Due to differences in the labelling requirements among regulatory authorities around the world,...   \n11  [PK of mepolizumab was evaluated in participants using Cmax. PK samples were collected at pre-do...   \n12  [FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the ...   \n13  [GLG is the total FDG uptake in the whole lung. A region of interest (ROI) was drawn around lung...   \n14  [Exacerbations are defined as the worsening of asthma which requires use of systemic corticoster...   \n15  [Percentage of participants who experienced >=1 HES flare during the 32-Week treatment period or...   \n16  [The average over the mean differences between benralizumab and placebo for change from baseline...   \n17  [sputum markers were classified as eosinophilic or non eosinophilic, safety was assessed by meas...   \n18  [LOAC was defined as any of the following:\\n\\nIncrease of asthma control questionnaire-5 (ACQ-5)...   \n19  [The primary efficacy analysis assessed the effect of CJM112 on the absolute change from baselin...   \n20  [The annual asthma exacerbation rate (AER) was calculated as the total number of observed exacer...   \n21  [The ACQ is a 7 question instrument. Each question has 7 possible answers of 0, 1, 2, 3, 4, 5, a...   \n22  [Percent of eosinophils was determined in the bronchoalveolar lavage fluid collected from the pa...   \n23                                                                                                   []   \n24  [An asthma exacerbation was defined as a worsening of asthma that led to any of the following:\\n...   \n25  [Secondary endpoints of inflammatory markers (sputum eosinophil percentages at 24 weeks) were me...   \n26  [AEs were collected from the Baseline visit until the follow-up visit (approx. 12 weeks post-las...   \n27  [Baseline (BL) dose was the prescribed optimized prednisone/prednisolone dose following the OCS ...   \n28  [Level of Tumour Necrosis Factor-alpha (TNF-\u03b1) [picograms per milliliter (pg/mL)] in blood at ba...   \n29  [The primary outcome will be the peak eosinophil/high powered field on repeat biopsy after the t...   \n30  [Eosinophils/high powered field(hpf) in the mid esophagus will be measured after 12 weeks of the...   \n31  [In asthmatic individuals, exposure to CCRE is expected to increase PMNs in the sputum. The sput...   \n\n                                                                                OutcomeMeasureTimeFrame  \\\n0   [Day 1 to Month 12, Day 1 (baseline, pre-dose), Week 16, Day 1 (baseline, pre-dose), Weeks 4, 8,...   \n1   [Day 1 to Week 52, Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16, Day 1 (baseline, pre-dose)...   \n2   [Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16, Day 1 (baseline, pre-dose), Weeks 4, 8, 12, ...   \n3   [Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observa...   \n4            [Baseline and at Week 32, Baseline and at Week 32, Up to Week 32, Baseline and at Week 32]   \n5   [Weeks 12, 24, 36 and 52, Baseline and Weeks 12, 24, 36 and 52, Baseline and Weeks 12, 24, 36 an...   \n6   [Baseline and Week 24, Baseline and Week 24, Baseline (Visit 2-latest pre-dose assessment) and W...   \n7   [Baseline up to Week 12, Baseline up to Week 12, Baseline up to Week 12, Baseline, Week 12, Base...   \n8   [Day 1 to up to Day 269; for participants who discontinued early for reasons other than study te...   \n9                                                                                      [Week 8, Week 4]   \n10                                                                     [Week 8, Week 8, Week 4, Week 4]   \n11  [Pre-dose on Weeks 4 and 8; Weeks 9, 12, 16 and 20 post-dose, Pre-dose on Weeks 4 and 8; Weeks 9...   \n12  [Baseline (Day 1), Week 16, Baseline (Day 1), Weeks 4, 8, 12, 16, Baseline (Day 1), Weeks 4, 8, ...   \n13  [Baseline (Day 1) of Part 1, Day 8, Baseline, Week 4, Baseline, Week 4, Baseline, Week 4, Baseli...   \n14  [Baseline (Week 0) to Week 172, Baseline (Week 0) to Week 172, Baseline (Week 0) to Week 168, Ba...   \n15  [Up to Week 32, Week 20 to Week 32, Weeks 4, 8, 12, 16, 20, 24, 28 and 32, Up to Week 32, Baseli...   \n16  [From first IP dose to Day 84, From first IP dose to Day 84, From first IP dose to Day 84, From ...   \n17                                                   [32 weeks, 32 weeks, every 4 weeks up to 32 weeks]   \n18  [Baseline (Week 0) up to Week 52, Baseline (Week 0) up to Week 52, Baseline (Week 0) up to Week ...   \n19  [Baseline, Day 92, Baseline, Day 92, Baseline, Day 92, Baseline, Day 92, Baseline, Day 92, 85 days]   \n20  [Week 1 up to Week 52, Baseline up to Week 66, Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4,...   \n21  [Baseline through End of Therapy (up to 15 weeks), Baseline, End of Therapy (up to 15 weeks), Ba...   \n22                  [before and after up to 3 months of Mepo., before and after up to 3 months of Mepo]   \n23                                                                                           [16 weeks]   \n24  [Baseline (Week 0) up to Week 24, Baseline (Week 0) and Week 24, Baseline (Week 0) and Week 24, ...   \n25                               [24 weeks, 24 weeks, 24 weeks, 24 weeks, 24 weeks, 24 weeks, 24 weeks]   \n26  [From Baseline visit until the follow-up visit (approximately [approx.] week 60 [12 weeks post-l...   \n27  [Baseline; Weeks 20 to 24, Baseline; Weeks 20 to 24, Weeks 20 to 24, Weeks 20 to 24, Baseline; W...   \n28  [Baseline (Visit 1), Baseline (Visit 1), follow-up visit 28 days after baseline (Visit 2), follo...   \n29                                                  [16 weeks, 16 weeks, 16 weeks, Conclusion of study]   \n30                                                                                           [12 weeks]   \n31  [after 14 days of gamma tocopherol or placebo treatment, after 14 days of gamma tocopherol or pl...   \n\n                                                                                OutcomeMeasurementValue  \\\n0   [2.115, 0.859, 0.122, 0.223, 0.094, 0.187, 0.777, 0.987, -0.660, -0.857, NA, NA, 0.080, 0.115, -...   \n1   [1.804, 0.904, 0.110, 0.248, 0.695, 0.933, -0.676, -0.941, 34.9, NA, 0.109, 0.167, -0.36, -0.64,...   \n2   [0.126, 0.242, 0.286, 0.172, 0.220, 0.301, -0.145, -0.114, 0.089, 0.8, 4.9, 7.5, 0.8, 5.5, 6.7, ...   \n3   [359, 385, 744, 31, 47, 78, 49, 41, 90, 6, 12, 18, 33, 45, 78, 1, 2, 3, 344, 367, 711, 78, 82, 1...   \n4                                                                            [-1.45, -19.0, 1.18, 0.22]   \n5   [31.8, 20.2, 49.3, 32.3, 56.0, 40.3, 60.7, 47.1, 6.03, 1.16, 6.58, 1.03, 6.48, 1.20, 6.17, 1.00,...   \n6                                                          [-7.9, -15.6, 56, 176, 55, 73, -0.40, -0.80]   \n7   [44.2, 5.8, 19.2, 1.9, 19.2, 1.9, 9.6, 1.9, 5.8, 0.0, 0.0, 0.0, 0.058, 0.038, 0.245, 0.058, 0.46...   \n8   [102, 114, 7, 6, 5, 11, 0, 0, 2, 0, 0, 0, 8, 5, 1, 0, 4, 2, 2, 0, 0, 1, 2, 0, 1, 1, 0, 1, 12, 10...   \n9                                                                                            [100, 100]   \n10                                                                                     [99, 98, 98, 96]   \n11  [12.8188, 16.3412, 10.1960, 508.23, 675.20, 454.39, 20.9583, 21.8420, 23.5582, 0.1968, 0.1481, 0...   \n12  [-0.2778, 0.0229, 0.175, 0.251, -0.614, -0.737, -0.2944, 0.0271, 0.164, 0.224, 0.199, 0.249, 0.1...   \n13                                                                               [668.08, 621.71, 1, 0]   \n14  [0.93, 315, 84, -0.16, -0.15, -0.21, -0.17, -0.18, -0.08, -0.03, -0.12, -0.06, -0.01, -0.09, 0.3...   \n15  [56, 28, 35, 17, 7.4, 5.6, 14.9, 7.4, 26.2, 9.3, 33.8, 13.0, 41.3, 13.0, 48.9, 14.8, 50.8, 20.5,...   \n16  [0.21, 0.132, 0.22, 0.203, 0.209, 0.149, -0.415, -0.208, -88.55, 11.55, 0.104, 0.081, 0.125, 0.0...   \n17                                                                                   [0, 0, 7, 6, 7, 6]   \n18  [24, 24, 24, 24, 0.56, 0.59, 0.79, 0.82, 13, 16, 100, 100, 2.24, 2.18, 2.36, 2.39, 325.33, 325.6...   \n19                               [0.043, 0.016, 1.064, 0.151, -0.93, -0.71, -0.83, -0.60, 38, 19, 8, 4]   \n20  [0.57, 0.65, 0.37, 0.34, 34.7, 182, 869, 17.3, 9.10, 8.69, 3.8, 42.0, 30.9, 25.6, 2.7479, 2.6479...   \n21  [-0.7, -0.3, 55, 36, 45, 64, 0.18, -0.08, 6.2, -2.4, -82.0, 45.9, 8, 19, 38, 42, 3, 1, 12, 8, 0,...   \n22                                                                                   [73, 31, 409, 447]   \n23                                                                                          [0.6, -7.5]   \n24  [0.94, 1.86, -23.06, -14.94, 0.30, 0.14, -1.47, -1.01, 123, 107, 27.17, 7.06, 16.47, -6.61, 17.7...   \n25  [2.33, 3.60, 1.60, 3.26, 86.00, 72.53, 89.33, 79.84, 334545, 26,300, 3602, 317778, 17.60, 15.18,...   \n26  [558, 119, 94, 1, 0, 31, 615, 0, 31, 0.93, -0.09, -0.11, -0.05, -0.10, -0.09, 0.20, 67, 50, 29, ...   \n27       [7, 16, 5, 12, 10, 9, 7, 7, 37, 25, 22, 37, 44, 32, 21, 37, 45, 32, 5, 10, 61, 59, 0.0, -50.0]   \n28       [5.3, 9.3, 10.6, 15.7, 71.3, 65.2, 245.0, 133.9, 5.8, 8.1, 5.2, 16.4, 47.7, 86.1, 105.1, 37.4]   \n29                                                                                                   []   \n30                                                                                                  [8]   \n31                                                       [11.7, 20.1, 2.6, 9.5, 20.2, 16.3, 21.4, 21.4]   \n\n                                                                            OutcomeMeasureUnitOfMeasure  \n0   [CAEs in 52 weeks, liters, liters, units on a scale, units on a scale, weeks, units on a scale, ...  \n1   [CAEs in 52 weeks, liters, units on a scale, units on a scale, weeks, units on a scale, puffs/da...  \n2   [liters, liters, liters/second, percentage of predicted FEV1, units on a scale, units on a scale...  \n3   [participants, participants, liters, percentage of predicted FEV1, liters, liters/second, # puff...  \n4                             [Scores on a scale, Scores on a scale, Exacerbation rate per year, Ratio]  \n5           [Percentage of participants, Ratio, Percentage of participants, Percentage of participants]  \n6                  [Scores on a scale, Milliliters (mL), Percentage of participants, Scores on a scale]  \n7   [percentage of participants, Probability of asthma exacerbation, percentage of participants, Lit...  \n8   [Participants, Participants, Participants, Participants, Participants, CAEs / year, CAEs / year,...  \n9                                              [Percentage of participants, Percentage of participants]  \n10  [Percentage of participants, Percentage of Participants, Percentage of participants, Percentage ...  \n11  [Microgram (ug) per mL, Day*ug per mL, Days, Liter (L) per day, Ratio of eosinophils in blood, P...  \n12  [FEV1 liters/ eosinophils 10^9/liter, liters, units on a scale, FEV1 liters/ eosinophils 10^9/li...  \n13                                                       [cubic centimeters (cm^3), cm^3, Participants]  \n14  [Exacerbations per year, Participants, Scores on a scale, Milliliter, Participants, Participants...  \n15  [Percentage of participants, Percentage of participants, Probability expressed as percentage, Fl...  \n16  [Liter, Liter, Percent change, Liter, Liter, Percentage of Participants, Score on a scale, Score...  \n17                                                           [Participants, Participants, Participants]  \n18  [Participants, Participants, scores on a scale, scores on a scale, Participants, percentage of p...  \n19              [Liters, Percent predicted, units on scale, units on scale, Participants, Participants]  \n20  [AER events/person-year, microgram per milliliter, microgram per milliliter, percentage of parti...  \n21  [units on a scale, percentage of participants, L, percent predicted FEV1, percent change in eosi...  \n22                                                      [percent of bronchoalveolar eosinophils, pg/ml]  \n23                                                            [perecentage of eos per high power field]  \n24  [Events/year, Scores on a scale, Liters (L), Scores on a scale, Participants, L/minute, Scores o...  \n25            [percentage of eosinophils, percentage of neutrophils, pg/ml, pg/ml, ratio, pg/ml, pg/ml]  \n26  [Participants, Participants, Exacerbations per year, Score on scale, Milliliters (mL), Participa...  \n27           [Participants, Participants, Participants, Participants, Percentage reduction in OCS dose]  \n28                                                                         [pg/mL, pg/mL, pg/mL, pg/mL]  \n29                                                                                                   []  \n30                                                                                    [Eosinophils/HPF]  \n31  [change in percentage of PMNs in sputum, eosinophils per mg sputum, % of labeled particles clear...  ",
                        "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Rank</th>\n      <th>NCTId</th>\n      <th>BriefTitle</th>\n      <th>Condition</th>\n      <th>Phase</th>\n      <th>StudyType</th>\n      <th>EnrollmentCount</th>\n      <th>StartDate</th>\n      <th>PrimaryCompletionDate</th>\n      <th>EligibilityCriteria</th>\n      <th>InterventionName</th>\n      <th>ArmGroupInterventionName</th>\n      <th>ArmGroupDescription</th>\n      <th>InterventionArmGroupLabel</th>\n      <th>OutcomeMeasureType</th>\n      <th>OutcomeMeasureTitle</th>\n      <th>OutcomeMeasureDescription</th>\n      <th>OutcomeMeasureTimeFrame</th>\n      <th>OutcomeMeasurementValue</th>\n      <th>OutcomeMeasureUnitOfMeasure</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>4</td>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>464</td>\n      <td>March 2011</td>\n      <td>April 2014</td>\n      <td>Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses., Res...</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment, Change From Ba...</td>\n      <td>[An exacerbation event was considered a CAE if the patient met either or both of the criteria li...</td>\n      <td>[Day 1 to Month 12, Day 1 (baseline, pre-dose), Week 16, Day 1 (baseline, pre-dose), Weeks 4, 8,...</td>\n      <td>[2.115, 0.859, 0.122, 0.223, 0.094, 0.187, 0.777, 0.987, -0.660, -0.857, NA, NA, 0.080, 0.115, -...</td>\n      <td>[CAEs in 52 weeks, liters, liters, units on a scale, units on a scale, weeks, units on a scale, ...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>6</td>\n      <td>NCT01287039</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...</td>\n      <td>Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>489</td>\n      <td>April 2011</td>\n      <td>December 2013</td>\n      <td>Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses., Res...</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment, Change From Ba...</td>\n      <td>[An exacerbation event was considered a CAE if the patient met either or both of the criteria li...</td>\n      <td>[Day 1 to Week 52, Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16, Day 1 (baseline, pre-dose)...</td>\n      <td>[1.804, 0.904, 0.110, 0.248, 0.695, 0.933, -0.676, -0.941, 34.9, NA, 0.109, 0.167, -0.36, -0.64,...</td>\n      <td>[CAEs in 52 weeks, liters, units on a scale, units on a scale, weeks, units on a scale, puffs/da...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>8</td>\n      <td>NCT01270464</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...</td>\n      <td>Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>315</td>\n      <td>February 2011</td>\n      <td>September 2013</td>\n      <td>Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab]</td>\n      <td>[Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses., 0.3 mg/kg,...</td>\n      <td>[Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed M...</td>\n      <td>[FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fr...</td>\n      <td>[Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16, Day 1 (baseline, pre-dose), Weeks 4, 8, 12, ...</td>\n      <td>[0.126, 0.242, 0.286, 0.172, 0.220, 0.301, -0.145, -0.114, 0.089, 0.8, 4.9, 7.5, 0.8, 5.5, 6.7, ...</td>\n      <td>[liters, liters, liters/second, percentage of predicted FEV1, units on a scale, units on a scale...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>9</td>\n      <td>NCT01290887</td>\n      <td>Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/k...</td>\n      <td>Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>1052</td>\n      <td>June 2011</td>\n      <td>January 2015</td>\n      <td>Inclusion Criteria:\\n\\nWritten informed consent is obtained.\\nPatient must have completed treatm...</td>\n      <td>[Reslizumab]</td>\n      <td>[Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 mon...</td>\n      <td>[Reslizumab 3.0 mg/kg]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Primary, Secondary, Se...</td>\n      <td>[Participants With Treatment-Emergent Adverse Events, Participants With Treatment-Emergent Poten...</td>\n      <td>[An adverse event was defined in the protocol as any untoward medical occurrence that develops o...</td>\n      <td>[Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observa...</td>\n      <td>[359, 385, 744, 31, 47, 78, 49, 41, 90, 6, 12, 18, 33, 45, 78, 1, 2, 3, 344, 367, 711, 78, 82, 1...</td>\n      <td>[participants, participants, liters, percentage of predicted FEV1, liters, liters/second, # puff...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>13</td>\n      <td>NCT02654145</td>\n      <td>Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients</td>\n      <td>Asthma</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>145</td>\n      <td>March 17, 2016</td>\n      <td>May 31, 2017</td>\n      <td>Inclusion Criteria:\\n\\nAt least 12 years of age at the time of signing the informed consent. For...</td>\n      <td>[Mepolizumab 100mg SC, Albuterol/salbutamol MDIs, Omalizumab]</td>\n      <td>[Drug: Mepolizumab 100mg SC, Drug: Albuterol/salbutamol MDIs, Drug: Omalizumab]</td>\n      <td>[Subjects with severe eosinophilic asthma who are receiving omalizumab will enter a run-in perio...</td>\n      <td>[Omalizumab switch to mepolizumab 100mg SC every 4 weeks, Omalizumab switch to mepolizumab 100mg...</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Mean Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 32, Mean Chan...</td>\n      <td>[The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma co...</td>\n      <td>[Baseline and at Week 32, Baseline and at Week 32, Up to Week 32, Baseline and at Week 32]</td>\n      <td>[-1.45, -19.0, 1.18, 0.22]</td>\n      <td>[Scores on a scale, Scores on a scale, Exacerbation rate per year, Ratio]</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>22</td>\n      <td>NCT02555371</td>\n      <td>Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>306</td>\n      <td>January 7, 2016</td>\n      <td>July 24, 2019</td>\n      <td>Inclusion Criteria:\\n\\nInformed Consent: Prior to commencing any study related activities, subje...</td>\n      <td>[Mepolizumab 100mg, Placebo]</td>\n      <td>[Biological: Mepolizumab 100mg, Biological: Mepolizumab 100mg, Drug: Placebo]</td>\n      <td>[There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up t...</td>\n      <td>[Arm Mepolizumab 100 mg, Arm Placebo, Arm Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Percentage of Participants With First Clinically Significant Exacerbation in Part C, Ratio to B...</td>\n      <td>[Clinically significant exacerbation was defined as worsening of asthma which requires use of sy...</td>\n      <td>[Weeks 12, 24, 36 and 52, Baseline and Weeks 12, 24, 36 and 52, Baseline and Weeks 12, 24, 36 an...</td>\n      <td>[31.8, 20.2, 49.3, 32.3, 56.0, 40.3, 60.7, 47.1, 6.03, 1.16, 6.58, 1.03, 6.48, 1.20, 6.17, 1.00,...</td>\n      <td>[Percentage of participants, Ratio, Percentage of participants, Percentage of participants]</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>24</td>\n      <td>NCT02281318</td>\n      <td>Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinoph...</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>556</td>\n      <td>December 11, 2014</td>\n      <td>June 10, 2016</td>\n      <td>Inclusion Criteria:\\n\\nAge: At least 12 years of age at the time of signing the informed consent...</td>\n      <td>[Mepolizumab, Placebo, SOC]</td>\n      <td>[Biological: Mepolizumab, Drug: SOC, Drug: Placebo, Drug: SOC]</td>\n      <td>[Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh ev...</td>\n      <td>[Mepolizumab SC, Placebo SC, Mepolizumab SC, Placebo SC]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 2...</td>\n      <td>[SGRQ consisted of 50 questions (scored from 0 to 100 where 0 indicates best and 100 indicates w...</td>\n      <td>[Baseline and Week 24, Baseline and Week 24, Baseline (Visit 2-latest pre-dose assessment) and W...</td>\n      <td>[-7.9, -15.6, 56, 176, 55, 73, -0.40, -0.80]</td>\n      <td>[Scores on a scale, Milliliters (mL), Percentage of participants, Scores on a scale]</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>27</td>\n      <td>NCT01312961</td>\n      <td>Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe E...</td>\n      <td>Asthma</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>104</td>\n      <td>March 2011</td>\n      <td>October 2012</td>\n      <td>Inclusion criteria:\\n\\nMedical diagnosis of persistent asthma for at least 12 months whose:\\n\\na...</td>\n      <td>[Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone mon...</td>\n      <td>[Drug: Placebo (for Dupilumab), Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticas...</td>\n      <td>[Placebo (for Dupilumab) subcutaneous (SC) injection once weekly (qw) for 12 weeks added to back...</td>\n      <td>[Dupilumab 300 mg qw, Placebo (for Dupilumab), Dupilumab 300 mg qw, Placebo (for Dupilumab), Dup...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants With Asthma Exacerbation, Time to First Asthma Exacerbation: Kaplan-...</td>\n      <td>[An asthma exacerbation was defined as the occurrence of any of the following: \u226530% reduction fr...</td>\n      <td>[Baseline up to Week 12, Baseline up to Week 12, Baseline up to Week 12, Baseline, Week 12, Base...</td>\n      <td>[44.2, 5.8, 19.2, 1.9, 19.2, 1.9, 9.6, 1.9, 5.8, 0.0, 0.0, 0.0, 0.058, 0.038, 0.245, 0.058, 0.46...</td>\n      <td>[percentage of participants, Probability of asthma exacerbation, percentage of participants, Lit...</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>28</td>\n      <td>NCT03052725</td>\n      <td>A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma</td>\n      <td>Eosinophils, Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>391</td>\n      <td>March 10, 2017</td>\n      <td>February 22, 2018</td>\n      <td>Inclusion Criteria:\\n\\n\u2022 Patient with eosinophilic asthma who completed the treatment period of ...</td>\n      <td>[reslizumab]</td>\n      <td>[Drug: reslizumab]</td>\n      <td>[Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or upp...</td>\n      <td>[reslizumab 110 mg]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Participants With Treatment-Emergent Adverse Events (TEAEs), Participants With Potentially Clin...</td>\n      <td>[An adverse event is any untoward medical occurrence, regardless of whether it has a causal rela...</td>\n      <td>[Day 1 to up to Day 269; for participants who discontinued early for reasons other than study te...</td>\n      <td>[102, 114, 7, 6, 5, 11, 0, 0, 2, 0, 0, 0, 8, 5, 1, 0, 4, 2, 2, 0, 0, 1, 2, 0, 1, 1, 0, 1, 12, 10...</td>\n      <td>[Participants, Participants, Participants, Participants, Participants, CAEs / year, CAEs / year,...</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>45</td>\n      <td>NCT03021304</td>\n      <td>Study of Mepolizumab Safety Syringe in Asthmatics</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>56</td>\n      <td>February 1, 2017</td>\n      <td>August 8, 2017</td>\n      <td>Inclusion Criteria:\\n\\nAge: At least 12 years of age inclusive, at the time of signing the infor...</td>\n      <td>[Mepolizumab]</td>\n      <td>[Drug: Mepolizumab]</td>\n      <td>[Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, sub...</td>\n      <td>[Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Percentage of Participants With Successful Self-administration of Their Observed Third Dose at ...</td>\n      <td>[During the clinic visits the Investigator or designee evaluated if the participants were able t...</td>\n      <td>[Week 8, Week 4]</td>\n      <td>[100, 100]</td>\n      <td>[Percentage of participants, Percentage of participants]</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>46</td>\n      <td>NCT03099096</td>\n      <td>Study of Mepolizumab Autoinjector in Asthmatics</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>159</td>\n      <td>May 4, 2017</td>\n      <td>November 30, 2017</td>\n      <td>Inclusion Criteria:\\n\\nAge: At least 12 years of age inclusive, at the time of signing the infor...</td>\n      <td>[Mepolizumab]</td>\n      <td>[Drug: Mepolizumab]</td>\n      <td>[Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the...</td>\n      <td>[Mepolizumab SC 100 mg/milliliter (mL) in autoinjector]</td>\n      <td>[Primary, Primary, Secondary, Secondary]</td>\n      <td>[Percentage of Participants With Successful Self-administration of Their Observed Third Dose at ...</td>\n      <td>[Due to differences in the labelling requirements among regulatory authorities around the world,...</td>\n      <td>[Week 8, Week 8, Week 4, Week 4]</td>\n      <td>[99, 98, 98, 96]</td>\n      <td>[Percentage of participants, Percentage of Participants, Percentage of participants, Percentage ...</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>47</td>\n      <td>NCT02377427</td>\n      <td>Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children</td>\n      <td>Asthma</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>36</td>\n      <td>August 25, 2015</td>\n      <td>December 7, 2016</td>\n      <td>Inclusion Criteria:\\n\\nBetween 6 and 11 years of age inclusive, at the time of screening.\\nDiagn...</td>\n      <td>[Mepolizumab]</td>\n      <td>[Drug: Mepolizumab, Drug: Mepolizumab]</td>\n      <td>[Participants with bodyweight &lt; 40 kg will receive 0.4 milliliter (mL) of reconstituted mepolizu...</td>\n      <td>[Mepolizumab 100 mg in Part A and B, Mepolizumab 40 mg in Part A and B]</td>\n      <td>[Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Prima...</td>\n      <td>[Maximum Plasma Concentration (Cmax) of Mepolizumab for Part A, Area Under Concentration Time Cu...</td>\n      <td>[PK of mepolizumab was evaluated in participants using Cmax. PK samples were collected at pre-do...</td>\n      <td>[Pre-dose on Weeks 4 and 8; Weeks 9, 12, 16 and 20 post-dose, Pre-dose on Weeks 4 and 8; Weeks 9...</td>\n      <td>[12.8188, 16.3412, 10.1960, 508.23, 675.20, 454.39, 20.9583, 21.8420, 23.5582, 0.1968, 0.1481, 0...</td>\n      <td>[Microgram (ug) per mL, Day*ug per mL, Days, Liter (L) per day, Ratio of eosinophils in blood, P...</td>\n    </tr>\n    <tr>\n      <th>12</th>\n      <td>51</td>\n      <td>NCT01508936</td>\n      <td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...</td>\n      <td>Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>511</td>\n      <td>February 2012</td>\n      <td>August 2013</td>\n      <td>Inclusion criteria:\\n\\nPatients are included in the study if all of the following criteria are m...</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Placebo intravenous injection every 4 weeks for a total of 4 doses., Reslizumab intravenous inj...</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis...</td>\n      <td>[FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the ...</td>\n      <td>[Baseline (Day 1), Week 16, Baseline (Day 1), Weeks 4, 8, 12, 16, Baseline (Day 1), Weeks 4, 8, ...</td>\n      <td>[-0.2778, 0.0229, 0.175, 0.251, -0.614, -0.737, -0.2944, 0.0271, 0.164, 0.224, 0.199, 0.249, 0.1...</td>\n      <td>[FEV1 liters/ eosinophils 10^9/liter, liters, units on a scale, FEV1 liters/ eosinophils 10^9/li...</td>\n    </tr>\n    <tr>\n      <th>13</th>\n      <td>58</td>\n      <td>NCT02937168</td>\n      <td>An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inf...</td>\n      <td>Asthma</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>5</td>\n      <td>May 8, 2017</td>\n      <td>May 24, 2017</td>\n      <td>Inclusion Criteria:\\n\\nMale or female, 18 through 50 years of age.\\nFemales that are either surg...</td>\n      <td>[Reslizumab, Fludeoxyglucose F 18 (FDG), Placebo]</td>\n      <td>[Drug: Fludeoxyglucose F 18 (FDG), Drug: Reslizumab, Drug: Fludeoxyglucose F 18 (FDG), Drug: Flu...</td>\n      <td>[Healthy participants will have 2 PET/CT scan in Part 1: within 7 days of eligibility being conf...</td>\n      <td>[Part 2: Reslizumab, Part 1: PET/CT Scan, Part 2: Placebo, Part 2: Reslizumab, Part 2: Placebo]</td>\n      <td>[Primary, Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Part 1: Average Global Lung Glycolysis (GLG) at Baseline (Day 1), Part 1: Average Global Lung G...</td>\n      <td>[GLG is the total FDG uptake in the whole lung. A region of interest (ROI) was drawn around lung...</td>\n      <td>[Baseline (Day 1) of Part 1, Day 8, Baseline, Week 4, Baseline, Week 4, Baseline, Week 4, Baseli...</td>\n      <td>[668.08, 621.71, 1, 0]</td>\n      <td>[cubic centimeters (cm^3), cm^3, Participants]</td>\n    </tr>\n    <tr>\n      <th>14</th>\n      <td>62</td>\n      <td>NCT02135692</td>\n      <td>A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>339</td>\n      <td>May 29, 2014</td>\n      <td>October 5, 2017</td>\n      <td>Inclusion Criteria:\\n\\nInformed Consent: Prior to commencing any study related activities, subje...</td>\n      <td>[Mepolizumab, SOC]</td>\n      <td>[Biological: Mepolizumab, Drug: SOC]</td>\n      <td>[All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approxi...</td>\n      <td>[Mepolizumab 100 mg, Mepolizumab 100 mg]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Annualized Rate of On-treatment Exacerbations Per Year, Number of Participants With Any On-trea...</td>\n      <td>[Exacerbations are defined as the worsening of asthma which requires use of systemic corticoster...</td>\n      <td>[Baseline (Week 0) to Week 172, Baseline (Week 0) to Week 172, Baseline (Week 0) to Week 168, Ba...</td>\n      <td>[0.93, 315, 84, -0.16, -0.15, -0.21, -0.17, -0.18, -0.08, -0.03, -0.12, -0.06, -0.01, -0.09, 0.3...</td>\n      <td>[Exacerbations per year, Participants, Scores on a scale, Milliliter, Participants, Participants...</td>\n    </tr>\n    <tr>\n      <th>15</th>\n      <td>75</td>\n      <td>NCT02836496</td>\n      <td>Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)</td>\n      <td>Hypereosinophilic Syndrome</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>108</td>\n      <td>March 7, 2017</td>\n      <td>August 8, 2019</td>\n      <td>Inclusion Criteria:\\n\\nCapable of giving signed informed consent/assent which includes complianc...</td>\n      <td>[Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or pre...</td>\n      <td>[Drug: Mepolizumab 300 mg, Drug: Active OCS capsules (5 mg prednisolone or prednisone), Drug: Pl...</td>\n      <td>[Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 w...</td>\n      <td>[Mepolizumab, Placebo, Mepolizumab, Placebo, Mepolizumab, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Percentage of Participants Who Experienced an HES Flare or Who Withdrew From the Study During t...</td>\n      <td>[Percentage of participants who experienced &gt;=1 HES flare during the 32-Week treatment period or...</td>\n      <td>[Up to Week 32, Week 20 to Week 32, Weeks 4, 8, 12, 16, 20, 24, 28 and 32, Up to Week 32, Baseli...</td>\n      <td>[56, 28, 35, 17, 7.4, 5.6, 14.9, 7.4, 26.2, 9.3, 33.8, 13.0, 41.3, 13.0, 48.9, 14.8, 50.8, 20.5,...</td>\n      <td>[Percentage of participants, Percentage of participants, Probability expressed as percentage, Fl...</td>\n    </tr>\n    <tr>\n      <th>16</th>\n      <td>95</td>\n      <td>NCT02869438</td>\n      <td>A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>233</td>\n      <td>November 9, 2016</td>\n      <td>August 1, 2018</td>\n      <td>Inclusion criteria\\n\\nWritten informed consent for study participation must be obtained prior to...</td>\n      <td>[Benralizumab, Placebo]</td>\n      <td>[Drug: Benralizumab, Other: Placebo]</td>\n      <td>[Benralizumab administered subcutaneously, Placebo administered subcutaneously]</td>\n      <td>[Benralizumab arm, Placebo arm]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in ...</td>\n      <td>[The average over the mean differences between benralizumab and placebo for change from baseline...</td>\n      <td>[From first IP dose to Day 84, From first IP dose to Day 84, From first IP dose to Day 84, From ...</td>\n      <td>[0.21, 0.132, 0.22, 0.203, 0.209, 0.149, -0.415, -0.208, -88.55, 11.55, 0.104, 0.081, 0.125, 0.0...</td>\n      <td>[Liter, Liter, Percent change, Liter, Liter, Percentage of Participants, Score on a scale, Score...</td>\n    </tr>\n    <tr>\n      <th>17</th>\n      <td>98</td>\n      <td>NCT00283504</td>\n      <td>A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic an...</td>\n      <td>ALLERGIC ASTHMA</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>13</td>\n      <td>January 2006</td>\n      <td>January 2009</td>\n      <td>Inclusion Criteria:\\n\\nModerate to severe allergic asthma, uncontrolled on conventional therapy\\...</td>\n      <td>[ANTI-IGE THERAPY (XOLAIR)]</td>\n      <td>[Drug: ANTI-IGE THERAPY (XOLAIR)]</td>\n      <td>[One arm:active drug]</td>\n      <td>[all patients received Xolair/active drug]</td>\n      <td>[Primary, Secondary, Secondary]</td>\n      <td>[Number of Participants With Change in Sputum Markers by End of Study, Number of Participants Wi...</td>\n      <td>[sputum markers were classified as eosinophilic or non eosinophilic, safety was assessed by meas...</td>\n      <td>[32 weeks, 32 weeks, every 4 weeks up to 32 weeks]</td>\n      <td>[0, 0, 7, 6, 7, 6]</td>\n      <td>[Participants, Participants, Participants]</td>\n    </tr>\n    <tr>\n      <th>18</th>\n      <td>102</td>\n      <td>NCT02898662</td>\n      <td>AZD1419 Ph2a Study</td>\n      <td>Asthma</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>81</td>\n      <td>October 12, 2016</td>\n      <td>September 25, 2018</td>\n      <td>Inclusion Criteria:\\n\\nMale and female patients 18 years and above\\nPhysician-diagnosed asthma r...</td>\n      <td>[AZD1419, Placebo]</td>\n      <td>[Drug: AZD1419, Drug: Placebo]</td>\n      <td>[Dose adaption of AZD1419, 4 mg or 8 mg or 1 mg based on occurence of AE's, Matching placebo]</td>\n      <td>[AZD1419, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Number of Participants With Events for Time to Loss of Asthma Control (LOAC) up to Week 52 - Co...</td>\n      <td>[LOAC was defined as any of the following:\\n\\nIncrease of asthma control questionnaire-5 (ACQ-5)...</td>\n      <td>[Baseline (Week 0) up to Week 52, Baseline (Week 0) up to Week 52, Baseline (Week 0) up to Week ...</td>\n      <td>[24, 24, 24, 24, 0.56, 0.59, 0.79, 0.82, 13, 16, 100, 100, 2.24, 2.18, 2.36, 2.39, 325.33, 325.6...</td>\n      <td>[Participants, Participants, scores on a scale, scores on a scale, Participants, percentage of p...</td>\n    </tr>\n    <tr>\n      <th>19</th>\n      <td>106</td>\n      <td>NCT03299686</td>\n      <td>Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Sever...</td>\n      <td>Asthma</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>118</td>\n      <td>November 6, 2017</td>\n      <td>April 8, 2019</td>\n      <td>Inclusion Criteria:\\n\\nPatients with a physician-diagnosed history of moderate to severe asthma ...</td>\n      <td>[CJM112, Placebo to CJM112]</td>\n      <td>[Drug: CJM112, Other: Placebo to CJM112]</td>\n      <td>[Study treatment, Placebo]</td>\n      <td>[CJM112, Placebo to CJM112]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Change From Baseline in Forced Expiratory Volume in One Second (FEV1), Change From Baseline in ...</td>\n      <td>[The primary efficacy analysis assessed the effect of CJM112 on the absolute change from baselin...</td>\n      <td>[Baseline, Day 92, Baseline, Day 92, Baseline, Day 92, Baseline, Day 92, Baseline, Day 92, 85 days]</td>\n      <td>[0.043, 0.016, 1.064, 0.151, -0.93, -0.71, -0.83, -0.60, 38, 19, 8, 4]</td>\n      <td>[Liters, Percent predicted, units on scale, units on scale, Participants, Participants]</td>\n    </tr>\n    <tr>\n      <th>20</th>\n      <td>111</td>\n      <td>NCT01238861</td>\n      <td>Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma</td>\n      <td>Asthma</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>964</td>\n      <td>December 2010</td>\n      <td>March 2013</td>\n      <td>Inclusion Criteria:\\n\\nAge 18 through 75 years at the time of screening\\nAdequate contraception ...</td>\n      <td>[Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg, Placebo]</td>\n      <td>[Other: Placebo, Biological: Benralizumab 2 mg, Biological: Benralizumab 20 mg, Biological: Benr...</td>\n      <td>[EOS+ (defined as ELEN Index [proprietary mathematical algorithm to predict sputum eosinophil's ...</td>\n      <td>[EOS+ Benralizumab (2 mg), EOS+ Benralizumab (20 mg), EOS+ Benralizumab (100 mg), EOS- Benralizu...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants, Dose Resp...</td>\n      <td>[The annual asthma exacerbation rate (AER) was calculated as the total number of observed exacer...</td>\n      <td>[Week 1 up to Week 52, Baseline up to Week 66, Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4,...</td>\n      <td>[0.57, 0.65, 0.37, 0.34, 34.7, 182, 869, 17.3, 9.10, 8.69, 3.8, 42.0, 30.9, 25.6, 2.7479, 2.6479...</td>\n      <td>[AER events/person-year, microgram per milliliter, microgram per milliliter, percentage of parti...</td>\n    </tr>\n    <tr>\n      <th>21</th>\n      <td>112</td>\n      <td>NCT00587288</td>\n      <td>Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma</td>\n      <td>Asthma</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>106</td>\n      <td>April 2008</td>\n      <td>March 2010</td>\n      <td>Inclusion Criteria:\\n\\nwritten informed consent\\nmale or female subjects aged \u2265 18 to 75 years a...</td>\n      <td>[Reslizumab, Saline]</td>\n      <td>[Biological: Reslizumab, Other: Saline]</td>\n      <td>[Reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles, S...</td>\n      <td>[Reslizumab 3 mg/kg, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Mean Change From Baseline to End of Therapy in Asthma Control Questionnaire (ACQ) Score, Percen...</td>\n      <td>[The ACQ is a 7 question instrument. Each question has 7 possible answers of 0, 1, 2, 3, 4, 5, a...</td>\n      <td>[Baseline through End of Therapy (up to 15 weeks), Baseline, End of Therapy (up to 15 weeks), Ba...</td>\n      <td>[-0.7, -0.3, 55, 36, 45, 64, 0.18, -0.08, 6.2, -2.4, -82.0, 45.9, 8, 19, 38, 42, 3, 1, 12, 8, 0,...</td>\n      <td>[units on a scale, percentage of participants, L, percent predicted FEV1, percent change in eosi...</td>\n    </tr>\n    <tr>\n      <th>22</th>\n      <td>115</td>\n      <td>NCT00802438</td>\n      <td>Eosinophilic Airway Inflammation and Mepolizumab</td>\n      <td>Asthma</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>38</td>\n      <td>June 1, 2008</td>\n      <td>March 1, 2013</td>\n      <td>Inclusion Criteria:\\n\\nMales or females age 18 to 50 yrs,\\nHistory of asthma based upon presence...</td>\n      <td>[mepolizumab]</td>\n      <td>[Biological: mepolizumab]</td>\n      <td>[up to 3 monthly doses of 750mg i.v. mepolizumab]</td>\n      <td>[Mepolizumab]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[The Primary Endpoint of the Study is the Percent of Eosinophils in the Bronchoalveolar Lavage F...</td>\n      <td>[Percent of eosinophils was determined in the bronchoalveolar lavage fluid collected from the pa...</td>\n      <td>[before and after up to 3 months of Mepo., before and after up to 3 months of Mepo]</td>\n      <td>[73, 31, 409, 447]</td>\n      <td>[percent of bronchoalveolar eosinophils, pg/ml]</td>\n    </tr>\n    <tr>\n      <th>23</th>\n      <td>126</td>\n      <td>NCT00123630</td>\n      <td>A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab</td>\n      <td>Esophagitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>30</td>\n      <td>November 2005</td>\n      <td>January 2010</td>\n      <td>Inclusion Criteria:\\n\\nMale or female subjects aged 12-60 years of age with EE as defined above\\...</td>\n      <td>[omalizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: omalizumab]</td>\n      <td>[placebo group, Xolair group]</td>\n      <td>[omalizumab, placebo]</td>\n      <td>[Primary]</td>\n      <td>[Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and ...</td>\n      <td>[]</td>\n      <td>[16 weeks]</td>\n      <td>[0.6, -7.5]</td>\n      <td>[perecentage of eos per high power field]</td>\n    </tr>\n    <tr>\n      <th>24</th>\n      <td>128</td>\n      <td>NCT03170271</td>\n      <td>A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontroll...</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>660</td>\n      <td>July 7, 2017</td>\n      <td>September 25, 2019</td>\n      <td>Inclusion Criteria:\\n\\nFemale and male patients aged 18 to 75 years inclusively at the time of V...</td>\n      <td>[Benralizumab (Medi-563), Placebo]</td>\n      <td>[Drug: Benralizumab (Medi-563), Drug: Placebo]</td>\n      <td>[Benralizumab (Medi563) Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 da...</td>\n      <td>[Benralizumab (Medi-563), Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24), Change From ...</td>\n      <td>[An asthma exacerbation was defined as a worsening of asthma that led to any of the following:\\n...</td>\n      <td>[Baseline (Week 0) up to Week 24, Baseline (Week 0) and Week 24, Baseline (Week 0) and Week 24, ...</td>\n      <td>[0.94, 1.86, -23.06, -14.94, 0.30, 0.14, -1.47, -1.01, 123, 107, 27.17, 7.06, 16.47, -6.61, 17.7...</td>\n      <td>[Events/year, Scores on a scale, Liters (L), Scores on a scale, Participants, L/minute, Scores o...</td>\n    </tr>\n    <tr>\n      <th>25</th>\n      <td>129</td>\n      <td>NCT00712335</td>\n      <td>The Effects of Montelukast on Smokers With Asthma</td>\n      <td>Asthmatic Smokers</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>105</td>\n      <td>February 2007</td>\n      <td>May 2011</td>\n      <td>Inclusion Criteria:\\n\\nAsthmatics:\\n\\nclinical history of asthma for at least 1 year\\nwith evide...</td>\n      <td>[Fluticasone Propionate, Montelukast, Salmeterol]</td>\n      <td>[Drug: Fluticasone Propionate, Drug: Salmeterol, Drug: Montelukast, Drug: Fluticasone Propionate...</td>\n      <td>[Asthmatic smokers treated with combination therapy:\\n\\nFluticasone propionate dosage - DPI 250 ...</td>\n      <td>[1, 3, 2, 4, 1, 3]</td>\n      <td>[Secondary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Sputum Eosinophil Percentages, Sputum Neutrophil Percentages, Sputum IL-8 Levels, Sputum GM-CSF...</td>\n      <td>[Secondary endpoints of inflammatory markers (sputum eosinophil percentages at 24 weeks) were me...</td>\n      <td>[24 weeks, 24 weeks, 24 weeks, 24 weeks, 24 weeks, 24 weeks, 24 weeks]</td>\n      <td>[2.33, 3.60, 1.60, 3.26, 86.00, 72.53, 89.33, 79.84, 334545, 26,300, 3602, 317778, 17.60, 15.18,...</td>\n      <td>[percentage of eosinophils, percentage of neutrophils, pg/ml, pg/ml, ratio, pg/ml, pg/ml]</td>\n    </tr>\n    <tr>\n      <th>26</th>\n      <td>134</td>\n      <td>NCT01842607</td>\n      <td>A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>651</td>\n      <td>May 27, 2013</td>\n      <td>March 13, 2015</td>\n      <td>Inclusion Criteria:\\n\\nFrench subjects: In France, a subject will be eligible for inclusion in t...</td>\n      <td>[Mepolizumab]</td>\n      <td>[Biological: Mepolizumab]</td>\n      <td>[Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously ...</td>\n      <td>[Mepolizumab Arm]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunog...</td>\n      <td>[AEs were collected from the Baseline visit until the follow-up visit (approx. 12 weeks post-las...</td>\n      <td>[From Baseline visit until the follow-up visit (approximately [approx.] week 60 [12 weeks post-l...</td>\n      <td>[558, 119, 94, 1, 0, 31, 615, 0, 31, 0.93, -0.09, -0.11, -0.05, -0.10, -0.09, 0.20, 67, 50, 29, ...</td>\n      <td>[Participants, Participants, Exacerbations per year, Score on scale, Milliliters (mL), Participa...</td>\n    </tr>\n    <tr>\n      <th>27</th>\n      <td>136</td>\n      <td>NCT01691508</td>\n      <td>Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>135</td>\n      <td>October 2012</td>\n      <td>December 2013</td>\n      <td>Inclusion Criteria:\\n\\nInformed Consent and Study Compliance: Subjects must be able to give writ...</td>\n      <td>[Mepolizumab, Placebo, OCS (prednisone/prednisolone)]</td>\n      <td>[Drug: Mepolizumab, Drug: OCS (prednisone/prednisolone), Drug: Placebo, Drug: OCS (prednisone/pr...</td>\n      <td>[Mepolizumab 100 mg subcutaneous once every 4 weeks upto Week 20, Placebo subcutaneous once ever...</td>\n      <td>[Mepolizumab, Placebo, Mepolizumab, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroi...</td>\n      <td>[Baseline (BL) dose was the prescribed optimized prednisone/prednisolone dose following the OCS ...</td>\n      <td>[Baseline; Weeks 20 to 24, Baseline; Weeks 20 to 24, Weeks 20 to 24, Weeks 20 to 24, Baseline; W...</td>\n      <td>[7, 16, 5, 12, 10, 9, 7, 7, 37, 25, 22, 37, 44, 32, 21, 37, 45, 32, 5, 10, 61, 59, 0.0, -50.0]</td>\n      <td>[Participants, Participants, Participants, Participants, Percentage reduction in OCS dose]</td>\n    </tr>\n    <tr>\n      <th>28</th>\n      <td>139</td>\n      <td>NCT02392481</td>\n      <td>Asthma Biomarker Study</td>\n      <td>Asthma</td>\n      <td>Unknown</td>\n      <td>Observational</td>\n      <td>69</td>\n      <td>July 16, 2015</td>\n      <td>January 3, 2017</td>\n      <td>Inclusion criteria:\\n\\nBody mass index (BMI) &gt;=18 and &lt;= 40 Non-smokers or ex-smokers with a cig...</td>\n      <td>[Biofluid sampling]</td>\n      <td>[Procedure: Biofluid sampling]</td>\n      <td>[]</td>\n      <td>[Healthy subjects]</td>\n      <td>[Primary, Primary, Secondary, Secondary]</td>\n      <td>[Level of Tumour Necrosis Factor-alpha (TNF-\u03b1) in Blood at Baseline (Visit 1), Level of Interleu...</td>\n      <td>[Level of Tumour Necrosis Factor-alpha (TNF-\u03b1) [picograms per milliliter (pg/mL)] in blood at ba...</td>\n      <td>[Baseline (Visit 1), Baseline (Visit 1), follow-up visit 28 days after baseline (Visit 2), follo...</td>\n      <td>[5.3, 9.3, 10.6, 15.7, 71.3, 65.2, 245.0, 133.9, 5.8, 8.1, 5.2, 16.4, 47.7, 86.1, 105.1, 37.4]</td>\n      <td>[pg/mL, pg/mL, pg/mL, pg/mL]</td>\n    </tr>\n    <tr>\n      <th>29</th>\n      <td>147</td>\n      <td>NCT01821898</td>\n      <td>Eosinophilic Esophagitis Clinical Therapy Comparison Trial</td>\n      <td>Eosinophilic Esophagitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>3</td>\n      <td>July 9, 2013</td>\n      <td>September 24, 2018</td>\n      <td>Inclusion Criteria\\n\\nSigned written informed consent and assent if applicable prior to performi...</td>\n      <td>[Oral Budesonide, Elimination diet]</td>\n      <td>[Drug: Oral Budesonide, Other: Elimination diet]</td>\n      <td>[Oral Budesonide, Elimination diet]</td>\n      <td>[Positive for food allergy: Group A, Positive for food allergy: Group B]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Peak Number of Eosinophils/High Powered Field, Quality of Life Survey Score, Symptom Score, Exp...</td>\n      <td>[The primary outcome will be the peak eosinophil/high powered field on repeat biopsy after the t...</td>\n      <td>[16 weeks, 16 weeks, 16 weeks, Conclusion of study]</td>\n      <td>[]</td>\n      <td>[]</td>\n    </tr>\n    <tr>\n      <th>30</th>\n      <td>151</td>\n      <td>NCT01458418</td>\n      <td>A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children</td>\n      <td>Eosinophilic Esophagitis</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>4</td>\n      <td>December 2011</td>\n      <td>February 2015</td>\n      <td>Inclusion Criteria:\\n\\nMales and females aged 2-17\\nPresence of more than 15 eosinophils per hpf...</td>\n      <td>[Montelukast, placebo, 5 mg Montelukast]</td>\n      <td>[Drug: Montelukast, Drug: 5 mg Montelukast, Other: placebo]</td>\n      <td>[Subjects will receive two 5mg tablets of Montelukast/day., Subjects will receive one 5mg tablet...</td>\n      <td>[Montelukast 10 mg/day, placebo, Montelukast 5mg/day]</td>\n      <td>[Primary]</td>\n      <td>[Eosinophil Count]</td>\n      <td>[Eosinophils/high powered field(hpf) in the mid esophagus will be measured after 12 weeks of the...</td>\n      <td>[12 weeks]</td>\n      <td>[8]</td>\n      <td>[Eosinophils/HPF]</td>\n    </tr>\n    <tr>\n      <th>31</th>\n      <td>168</td>\n      <td>NCT02104505</td>\n      <td>Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS</td>\n      <td>Mild, Allergic Asthma</td>\n      <td>Phase 1, Phase 2</td>\n      <td>Interventional</td>\n      <td>23</td>\n      <td>November 2015</td>\n      <td>September 2016</td>\n      <td>Inclusion Criteria:\\n\\nAge 18-50 of both genders\\nNegative pregnancy test for females who are no...</td>\n      <td>[Gamma Tocopherol 700 mg capsules,, Placebo]</td>\n      <td>[Drug: Gamma Tocopherol 700 mg capsules,, Drug: Placebo]</td>\n      <td>[Gamma Tocopherol supplement, Safflower oil capsules]</td>\n      <td>[700 mg Gamma Tocopherol daily x 14days, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Comparison of Change in Sputum Percent Neutrophils (PMN)s Following Inhaled Clinical Center Ref...</td>\n      <td>[In asthmatic individuals, exposure to CCRE is expected to increase PMNs in the sputum. The sput...</td>\n      <td>[after 14 days of gamma tocopherol or placebo treatment, after 14 days of gamma tocopherol or pl...</td>\n      <td>[11.7, 20.1, 2.6, 9.5, 20.2, 16.3, 21.4, 21.4]</td>\n      <td>[change in percentage of PMNs in sputum, eosinophils per mg sputum, % of labeled particles clear...</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "asthma_study_table.shape",
            "execution_count": 7,
            "outputs": [
                {
                    "output_type": "execute_result",
                    "execution_count": 7,
                    "data": {
                        "text/plain": "(32, 20)"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "The eosinophilic asthma query returned 32 unique studies across all phases.  As can be seen in the table above, each study contains multiple points of outcome data, contained in lists in the respective columns of interest.\n\n\nUsing the Study class's extract_outcomes function, and the Query class's build_outcomes_table functions, I will extract all the individual outcomes found in each study, and compile a master data table containing individual entries for each outcome measure."
        },
        {
            "metadata": {
                "scrolled": true
            },
            "cell_type": "code",
            "source": "asthma_outcome_table = asthma.build_outcome_table()\nasthma_outcome_table.shape",
            "execution_count": 8,
            "outputs": [
                {
                    "output_type": "execute_result",
                    "execution_count": 8,
                    "data": {
                        "text/plain": "(187, 12)"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "Looks like across the 32 studies returned in the eosinophilic asthma query, there were 187 total endpoints reported.  I want to better understand how many times a certain endpoint was reported (i.e., change from baseline in forced expiratory volume in 1 second, \"FEV1\").  However, I notice many of the studies report the same outcome, but the outcome measure title / description are written slightly differently.\n\nI built a search function to take a series of keywords and identify how many individual endpoints contain all of the search keywords in the 'OutcomeMeasureTitle' column.  First I tokenize the 'OutcomeMeasureTitle' column for each endpoint, and strip all whitespace and parentheses to help control for inconsistent reporting of endpoints - I then do the same for the list of keywords in the user's search expression.  A match is identified if all keywords are found in the tokenized list in the 'OutcomeMeasureTitleTokenized' column."
        },
        {
            "metadata": {
                "scrolled": false
            },
            "cell_type": "code",
            "source": "tokenize_column(asthma_outcome_table, 'OutcomeMeasureTitle', 'OutcomeMeasureTitleTokenized')",
            "execution_count": 9,
            "outputs": []
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "asthma_outcome_table.head(10)",
            "execution_count": 10,
            "outputs": [
                {
                    "output_type": "execute_result",
                    "execution_count": 10,
                    "data": {
                        "text/plain": "         NCTId  \\\n0  NCT01285323   \n1  NCT01285323   \n2  NCT01285323   \n3  NCT01285323   \n4  NCT01285323   \n5  NCT01285323   \n6  NCT01285323   \n7  NCT01285323   \n8  NCT01285323   \n9  NCT01285323   \n\n                                                                                       BriefTitle  \\\n0  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n1  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n2  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n3  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n4  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n5  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n6  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n7  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n8  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n9  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n\n     Phase       InterventionName           ArmGroupInterventionName  \\\n0  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n1  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n2  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n3  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n4  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n5  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n6  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n7  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n8  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n9  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n\n         InterventionArmGroupLabel OutcomeMeasureType  \\\n0  [Reslizumab 3.0 mg/kg, Placebo]            Primary   \n1  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n2  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n3  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n4  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n5  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n6  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n7  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n8  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n9  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n\n                                                                                   OutcomeMeasureTitle  \\\n0                      Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment   \n1                       Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) At Week 16   \n2  Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...   \n3                       Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) to Week 16   \n4  Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for R...   \n5                          Kaplan-Meier Estimates for Time to First Clinical Asthma Exacerbation (CAE)   \n6  Change From Baseline in Asthma Symptom Utility Index (ASUI) Over 16 Weeks Using Mixed Model for ...   \n7  Change From Baseline in Short-Acting Beta-Agonist (SABA) Use Over 16 Weeks Using Mixed Model for...   \n8  Change From Baseline in Blood Eosinophil Count Over 16 Weeks and 52 Weeks Using Mixed Model for ...   \n9                                            Participants With Treatment-Emergent Adverse Events TEAE)   \n\n                                                                             OutcomeMeasureDescription  \\\n0  An exacerbation event was considered a CAE if the patient met either or both of the criteria lis...   \n1  FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n2  FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n3  The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The que...   \n4  The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions ...   \n5  An exacerbation event was considered a CAE if the patient met either or both of the criteria lis...   \n6  The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma sympto...   \n7  SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit p...   \n8  The blood eosinophil counts were measured using a standard complete blood count (CBC) with diffe...   \n9  An adverse event (AE) was defined in the protocol as any untoward medical occurrence that develo...   \n\n                                                                               OutcomeMeasureTimeFrame  \\\n0                                                                                    Day 1 to Month 12   \n1                                                                  Day 1 (baseline, pre-dose), Week 16   \n2                                                    Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16   \n3                                                                  Day 1 (baseline, pre-dose), Week 16   \n4                                                       Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16   \n5                                               Day 1 to Day 526 (longest treatment time plus 2 weeks)   \n6                                                       Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16   \n7                                                       Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16   \n8  Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early with...   \n9  Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observat...   \n\n                               OutcomeMeasurementValue  \\\n0    [2.115, 0.859, 0.122, 0.223, 0.094, 0.187, 0.777]   \n1        [0.987, -0.660, -0.857, NA, NA, 0.080, 0.115]   \n2  [-0.44, -0.50, -0.076, -0.555, -0.076, -0.565, 201]   \n3                       [177, 36, 67, 140, 98, 25, 12]   \n4                          [27, 34, 14, 22, 13, 11, 0]   \n5                              [1, 9, 8, 0, 0, 23, 18]   \n6                [1.660, 0.646, 0.047, 0.033, 5, 4, 0]   \n7                                [1, 5, 2, 3, 2, 7, 3]   \n8                              [11, 9, 3, 3, 3, 10, 0]   \n9                            [1, 5, 6, 10, 8, 168, 10]   \n\n  OutcomeMeasureUnitOfMeasure  \\\n0            CAEs in 52 weeks   \n1                      liters   \n2                      liters   \n3            units on a scale   \n4            units on a scale   \n5                       weeks   \n6            units on a scale   \n7          SABA puffs per day   \n8     10^9 blood eosinophil/L   \n9                participants   \n\n                                                                          OutcomeMeasureTitleTokenized  \n0            [frequency, of, clinical, asthma, exacerbations, caes, during, 12, months, of, treatment]  \n1          [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16]  \n2  [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...  \n3           [change, from, baseline, in, asthma, quality, of, life, questionnaire, aqlq, to, week, 16]  \n4  [change, from, baseline, in, asthma, control, questionnaire, acq, over, 16, weeks, using, mixed,...  \n5                 [kaplan-meier, estimates, for, time, to, first, clinical, asthma, exacerbation, cae]  \n6  [change, from, baseline, in, asthma, symptom, utility, index, asui, over, 16, weeks, using, mixe...  \n7  [change, from, baseline, in, short-acting, beta-agonist, saba, use, over, 16, weeks, using, mixe...  \n8  [change, from, baseline, in, blood, eosinophil, count, over, 16, weeks, and, 52, weeks, using, m...  \n9                                      [participants, with, treatment-emergent, adverse, events, teae]  ",
                        "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>NCTId</th>\n      <th>BriefTitle</th>\n      <th>Phase</th>\n      <th>InterventionName</th>\n      <th>ArmGroupInterventionName</th>\n      <th>InterventionArmGroupLabel</th>\n      <th>OutcomeMeasureType</th>\n      <th>OutcomeMeasureTitle</th>\n      <th>OutcomeMeasureDescription</th>\n      <th>OutcomeMeasureTimeFrame</th>\n      <th>OutcomeMeasurementValue</th>\n      <th>OutcomeMeasureUnitOfMeasure</th>\n      <th>OutcomeMeasureTitleTokenized</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Primary</td>\n      <td>Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment</td>\n      <td>An exacerbation event was considered a CAE if the patient met either or both of the criteria lis...</td>\n      <td>Day 1 to Month 12</td>\n      <td>[2.115, 0.859, 0.122, 0.223, 0.094, 0.187, 0.777]</td>\n      <td>CAEs in 52 weeks</td>\n      <td>[frequency, of, clinical, asthma, exacerbations, caes, during, 12, months, of, treatment]</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) At Week 16</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 1 (baseline, pre-dose), Week 16</td>\n      <td>[0.987, -0.660, -0.857, NA, NA, 0.080, 0.115]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16]</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16</td>\n      <td>[-0.44, -0.50, -0.076, -0.555, -0.076, -0.565, 201]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) to Week 16</td>\n      <td>The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The que...</td>\n      <td>Day 1 (baseline, pre-dose), Week 16</td>\n      <td>[177, 36, 67, 140, 98, 25, 12]</td>\n      <td>units on a scale</td>\n      <td>[change, from, baseline, in, asthma, quality, of, life, questionnaire, aqlq, to, week, 16]</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for R...</td>\n      <td>The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions ...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16</td>\n      <td>[27, 34, 14, 22, 13, 11, 0]</td>\n      <td>units on a scale</td>\n      <td>[change, from, baseline, in, asthma, control, questionnaire, acq, over, 16, weeks, using, mixed,...</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Kaplan-Meier Estimates for Time to First Clinical Asthma Exacerbation (CAE)</td>\n      <td>An exacerbation event was considered a CAE if the patient met either or both of the criteria lis...</td>\n      <td>Day 1 to Day 526 (longest treatment time plus 2 weeks)</td>\n      <td>[1, 9, 8, 0, 0, 23, 18]</td>\n      <td>weeks</td>\n      <td>[kaplan-meier, estimates, for, time, to, first, clinical, asthma, exacerbation, cae]</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Asthma Symptom Utility Index (ASUI) Over 16 Weeks Using Mixed Model for ...</td>\n      <td>The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma sympto...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16</td>\n      <td>[1.660, 0.646, 0.047, 0.033, 5, 4, 0]</td>\n      <td>units on a scale</td>\n      <td>[change, from, baseline, in, asthma, symptom, utility, index, asui, over, 16, weeks, using, mixe...</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Short-Acting Beta-Agonist (SABA) Use Over 16 Weeks Using Mixed Model for...</td>\n      <td>SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit p...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16</td>\n      <td>[1, 5, 2, 3, 2, 7, 3]</td>\n      <td>SABA puffs per day</td>\n      <td>[change, from, baseline, in, short-acting, beta-agonist, saba, use, over, 16, weeks, using, mixe...</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Blood Eosinophil Count Over 16 Weeks and 52 Weeks Using Mixed Model for ...</td>\n      <td>The blood eosinophil counts were measured using a standard complete blood count (CBC) with diffe...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early with...</td>\n      <td>[11, 9, 3, 3, 3, 10, 0]</td>\n      <td>10^9 blood eosinophil/L</td>\n      <td>[change, from, baseline, in, blood, eosinophil, count, over, 16, weeks, and, 52, weeks, using, m...</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Participants With Treatment-Emergent Adverse Events TEAE)</td>\n      <td>An adverse event (AE) was defined in the protocol as any untoward medical occurrence that develo...</td>\n      <td>Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observat...</td>\n      <td>[1, 5, 6, 10, 8, 168, 10]</td>\n      <td>participants</td>\n      <td>[participants, with, treatment-emergent, adverse, events, teae]</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "# \n\nI would now like to know how many endpoints relate to Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1), a common asthma endpoint.\n\n# "
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "search_results = search_outcomes(asthma_outcome_table, 'OutcomeMeasureTitleTokenized')\nsearch_results",
            "execution_count": 11,
            "outputs": [
                {
                    "output_type": "stream",
                    "name": "stdout",
                    "text": "Enter your search term here: \nchange baseline FEV1\n\nSearching outcomes that contain the following key terms:\n\n['change', 'baseline', 'fev1']\n"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 11,
                    "data": {
                        "text/plain": "    index        NCTId  \\\n0       1  NCT01285323   \n1       2  NCT01285323   \n2      15  NCT01287039   \n3      28  NCT01287039   \n4      40  NCT01270464   \n5      43  NCT01270464   \n6      71  NCT02281318   \n7      97  NCT01508936   \n8      98  NCT01508936   \n9     100  NCT01508936   \n10    101  NCT01508936   \n11    102  NCT01508936   \n12    116  NCT02135692   \n13    132  NCT02869438   \n14    135  NCT02869438   \n15    157  NCT03170271   \n16    170  NCT01842607   \n\n                                                                                             BriefTitle  \\\n0        A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n1        A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n2   A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...   \n3   A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...   \n4   A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...   \n5   A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...   \n6   Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinoph...   \n7   Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...   \n8   Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...   \n9   Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...   \n10  Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...   \n11  Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...   \n12     A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects   \n13  A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...   \n14  A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...   \n15  A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontroll...   \n16                           A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects   \n\n      Phase                    InterventionName  \\\n0   Phase 3               [Reslizumab, Placebo]   \n1   Phase 3               [Reslizumab, Placebo]   \n2   Phase 3               [Reslizumab, Placebo]   \n3   Phase 3               [Reslizumab, Placebo]   \n4   Phase 3               [Reslizumab, Placebo]   \n5   Phase 3               [Reslizumab, Placebo]   \n6   Phase 3         [Mepolizumab, Placebo, SOC]   \n7   Phase 3               [Reslizumab, Placebo]   \n8   Phase 3               [Reslizumab, Placebo]   \n9   Phase 3               [Reslizumab, Placebo]   \n10  Phase 3               [Reslizumab, Placebo]   \n11  Phase 3               [Reslizumab, Placebo]   \n12  Phase 3                  [Mepolizumab, SOC]   \n13  Phase 3             [Benralizumab, Placebo]   \n14  Phase 3             [Benralizumab, Placebo]   \n15  Phase 3  [Benralizumab (Medi-563), Placebo]   \n16  Phase 3                       [Mepolizumab]   \n\n                                          ArmGroupInterventionName  \\\n0                                [Drug: Placebo, Drug: Reslizumab]   \n1                                [Drug: Placebo, Drug: Reslizumab]   \n2                                [Drug: Placebo, Drug: Reslizumab]   \n3                                [Drug: Placebo, Drug: Reslizumab]   \n4              [Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab]   \n5              [Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab]   \n6   [Biological: Mepolizumab, Drug: SOC, Drug: Placebo, Drug: SOC]   \n7                                [Drug: Placebo, Drug: Reslizumab]   \n8                                [Drug: Placebo, Drug: Reslizumab]   \n9                                [Drug: Placebo, Drug: Reslizumab]   \n10                               [Drug: Placebo, Drug: Reslizumab]   \n11                               [Drug: Placebo, Drug: Reslizumab]   \n12                            [Biological: Mepolizumab, Drug: SOC]   \n13                            [Drug: Benralizumab, Other: Placebo]   \n14                            [Drug: Benralizumab, Other: Placebo]   \n15                  [Drug: Benralizumab (Medi-563), Drug: Placebo]   \n16                                       [Biological: Mepolizumab]   \n\n                                    InterventionArmGroupLabel  \\\n0                             [Reslizumab 3.0 mg/kg, Placebo]   \n1                             [Reslizumab 3.0 mg/kg, Placebo]   \n2                             [Reslizumab 3.0 mg/kg, Placebo]   \n3                             [Reslizumab 3.0 mg/kg, Placebo]   \n4   [Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo]   \n5   [Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo]   \n6    [Mepolizumab SC, Placebo SC, Mepolizumab SC, Placebo SC]   \n7                             [Reslizumab 3.0 mg/kg, Placebo]   \n8                             [Reslizumab 3.0 mg/kg, Placebo]   \n9                             [Reslizumab 3.0 mg/kg, Placebo]   \n10                            [Reslizumab 3.0 mg/kg, Placebo]   \n11                            [Reslizumab 3.0 mg/kg, Placebo]   \n12                   [Mepolizumab 100 mg, Mepolizumab 100 mg]   \n13                            [Benralizumab arm, Placebo arm]   \n14                            [Benralizumab arm, Placebo arm]   \n15                         [Benralizumab (Medi-563), Placebo]   \n16                                          [Mepolizumab Arm]   \n\n   OutcomeMeasureType  \\\n0           Secondary   \n1           Secondary   \n2           Secondary   \n3           Secondary   \n4             Primary   \n5           Secondary   \n6           Secondary   \n7             Primary   \n8           Secondary   \n9           Secondary   \n10          Secondary   \n11          Secondary   \n12          Secondary   \n13            Primary   \n14          Secondary   \n15          Secondary   \n16          Secondary   \n\n                                                                                    OutcomeMeasureTitle  \\\n0                        Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) At Week 16   \n1   Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...   \n2   Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...   \n3   Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...   \n4   Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...   \n5   Change From Baseline in % Predicted Expiratory Volume In 1 Second (FEV1) at Week 16 and at Endpoint   \n6   Mean Change From Baseline in Clinic Pre-bronchodilator Forced Expiratory Volume in One Second (F...   \n7   Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis Set   \n8   Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...   \n9   Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in FEV1 Subpopula...   \n10        Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 4, 8, 12, and 16   \n11  Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (% Predicted FEV1...   \n12                             Mean Change From Baseline in On-treatment Clinic Pre-bronchodilator FEV1   \n13  Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in P...   \n14                                Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1   \n15  Change From Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in First Second (FEV1) ...   \n16        Mean Change From Baseline in Clinic Pre-bronchodilator FEV1 Over the 52-week Treatment Period   \n\n                                                                              OutcomeMeasureDescription  \\\n0   FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n1   FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n2   FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n3   FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n4   FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n5   The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a fo...   \n6   FEV1 is the volume of air that can be forced out in one second after taking a deep breath. The c...   \n7   FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...   \n8   FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...   \n9   FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...   \n10  FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...   \n11  The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a fo...   \n12  FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Pre-broncho...   \n13  The average over the mean differences between benralizumab and placebo for change from baseline ...   \n14  Post baseline visits include Day 3, Day 7, Day 14, Day 28, Day 56, Day 84. [Note: Day 28, 56, 84...   \n15  Lung function was assessed by FEV1 which was measured by spirometry. Spirometry was performed by...   \n16  FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Pre-broncho...   \n\n                              OutcomeMeasureTimeFrame  \\\n0                 Day 1 (baseline, pre-dose), Week 16   \n1   Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16   \n2   Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16   \n3   Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16   \n4   Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16   \n5       Day 1 (baseline, pre-dose), Week 16, endpoint   \n6                                Baseline and Week 24   \n7                           Baseline (Day 1), Week 16   \n8                Baseline (Day 1), Weeks 4, 8, 12, 16   \n9                           Baseline (Day 1), Week 16   \n10           Baseline (Day 1), Weeks 4, 8, 12, and 16   \n11           Baseline (Day 1), Weeks 4, 8, 12, and 16   \n12                      Baseline (Week 0) to Week 168   \n13                       From first IP dose to Day 84   \n14                       From first IP dose to Day 84   \n15                      Baseline (Week 0) and Week 24   \n16                    From Baseline and up to Week 52   \n\n                                                    OutcomeMeasurementValue  \\\n0                             [0.987, -0.660, -0.857, NA, NA, 0.080, 0.115]   \n1                       [-0.44, -0.50, -0.076, -0.555, -0.076, -0.565, 201]   \n2                    [34.9, NA, 0.109, 0.167, -0.36, -0.64, -0.118, -0.584]   \n3                    [34.9, NA, 0.109, 0.167, -0.36, -0.64, -0.118, -0.584]   \n4    [0.126, 0.242, 0.286, 0.172, 0.220, 0.301, -0.145, -0.114, 0.089, 0.8]   \n5                                       [66, 59, 61, 4, 2, 7, 8, 6, 12, 10]   \n6                                                                 [56, 176]   \n7   [-0.2778, 0.0229, 0.175, 0.251, -0.614, -0.737, -0.2944, 0.0271, 0.164]   \n8               [0.224, 0.199, 0.249, 0.152, 0.277, 0.187, 0.255, 4.8, 6.7]   \n9           [0.235, 0.179, 0.243, 0.176, 0.284, 0.234, 0.246, 0.210, 0.184]   \n10             [0.270, 0.240, 0.136, 0.256, 0.179, 0.241, -0.1, -0.2, -0.2]   \n11             [-0.3, -0.2, -0.3, -0.4, -0.3, 0.010, -0.226, 0.036, -0.239]   \n12         [35, 3, 0, 1, 77, 199, 28, 0, 1.8, 0.6, 1.5, 2.0, 1.2, 1.8, 1.4]   \n13                                        [0.21, 0.132, 0.22, 0.203, 0.209]   \n14                                         [0.1, 0.122, 0.11, 0.138, 0.099]   \n15                                                  [123, 107, 27.17, 7.06]   \n16                                              [4, 0, 1, 0, 0, 0, 0, 0, 0]   \n\n            OutcomeMeasureUnitOfMeasure  \\\n0                                liters   \n1                                liters   \n2                                liters   \n3                                liters   \n4                                liters   \n5          percentage of predicted FEV1   \n6                      Milliliters (mL)   \n7   FEV1 liters/ eosinophils 10^9/liter   \n8                                liters   \n9   FEV1 liters/ eosinophils 10^9/liter   \n10                               liters   \n11         percentage of predicted FEV1   \n12                           Milliliter   \n13                                Liter   \n14                                Liter   \n15                           Liters (L)   \n16                     Milliliters (mL)   \n\n                                                                           OutcomeMeasureTitleTokenized  \n0           [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16]  \n1   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...  \n2   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...  \n3   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...  \n4   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...  \n5   [change, from, baseline, in, %, predicted, expiratory, volume, in, 1, second, fev1, at, week, 16...  \n6   [mean, change, from, baseline, in, clinic, pre-bronchodilator, forced, expiratory, volume, in, o...  \n7   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16, in, ...  \n8   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...  \n9   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16, in, ...  \n10  [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, weeks, 4,, 8,,...  \n11  [change, from, baseline, in, percent, predicted, forced, expiratory, volume, in, 1, second, %, p...  \n12                   [mean, change, from, baseline, in, on-treatment, clinic, pre-bronchodilator, fev1]  \n13  [change, from, baseline, visit, 4, to, day, 28, visit, 8),, day, 56, visit, 9),, and, day, 84, v...  \n14                     [change, from, baseline, visit, 4, to, post, baseline, visits, in, pre-bd, fev1]  \n15  [change, from, baseline, in, pre-bronchodilator, bd, forced, expiratory, volume, in, first, seco...  \n16  [mean, change, from, baseline, in, clinic, pre-bronchodilator, fev1, over, the, 52-week, treatme...  ",
                        "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>index</th>\n      <th>NCTId</th>\n      <th>BriefTitle</th>\n      <th>Phase</th>\n      <th>InterventionName</th>\n      <th>ArmGroupInterventionName</th>\n      <th>InterventionArmGroupLabel</th>\n      <th>OutcomeMeasureType</th>\n      <th>OutcomeMeasureTitle</th>\n      <th>OutcomeMeasureDescription</th>\n      <th>OutcomeMeasureTimeFrame</th>\n      <th>OutcomeMeasurementValue</th>\n      <th>OutcomeMeasureUnitOfMeasure</th>\n      <th>OutcomeMeasureTitleTokenized</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>1</td>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) At Week 16</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 1 (baseline, pre-dose), Week 16</td>\n      <td>[0.987, -0.660, -0.857, NA, NA, 0.080, 0.115]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16]</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>2</td>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16</td>\n      <td>[-0.44, -0.50, -0.076, -0.555, -0.076, -0.565, 201]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>15</td>\n      <td>NCT01287039</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16</td>\n      <td>[34.9, NA, 0.109, 0.167, -0.36, -0.64, -0.118, -0.584]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>28</td>\n      <td>NCT01287039</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16</td>\n      <td>[34.9, NA, 0.109, 0.167, -0.36, -0.64, -0.118, -0.584]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>40</td>\n      <td>NCT01270464</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab]</td>\n      <td>[Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo]</td>\n      <td>Primary</td>\n      <td>Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16</td>\n      <td>[0.126, 0.242, 0.286, 0.172, 0.220, 0.301, -0.145, -0.114, 0.089, 0.8]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>43</td>\n      <td>NCT01270464</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab]</td>\n      <td>[Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in % Predicted Expiratory Volume In 1 Second (FEV1) at Week 16 and at Endpoint</td>\n      <td>The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a fo...</td>\n      <td>Day 1 (baseline, pre-dose), Week 16, endpoint</td>\n      <td>[66, 59, 61, 4, 2, 7, 8, 6, 12, 10]</td>\n      <td>percentage of predicted FEV1</td>\n      <td>[change, from, baseline, in, %, predicted, expiratory, volume, in, 1, second, fev1, at, week, 16...</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>71</td>\n      <td>NCT02281318</td>\n      <td>Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinoph...</td>\n      <td>Phase 3</td>\n      <td>[Mepolizumab, Placebo, SOC]</td>\n      <td>[Biological: Mepolizumab, Drug: SOC, Drug: Placebo, Drug: SOC]</td>\n      <td>[Mepolizumab SC, Placebo SC, Mepolizumab SC, Placebo SC]</td>\n      <td>Secondary</td>\n      <td>Mean Change From Baseline in Clinic Pre-bronchodilator Forced Expiratory Volume in One Second (F...</td>\n      <td>FEV1 is the volume of air that can be forced out in one second after taking a deep breath. The c...</td>\n      <td>Baseline and Week 24</td>\n      <td>[56, 176]</td>\n      <td>Milliliters (mL)</td>\n      <td>[mean, change, from, baseline, in, clinic, pre-bronchodilator, forced, expiratory, volume, in, o...</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>97</td>\n      <td>NCT01508936</td>\n      <td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Primary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis Set</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...</td>\n      <td>Baseline (Day 1), Week 16</td>\n      <td>[-0.2778, 0.0229, 0.175, 0.251, -0.614, -0.737, -0.2944, 0.0271, 0.164]</td>\n      <td>FEV1 liters/ eosinophils 10^9/liter</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16, in, ...</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>98</td>\n      <td>NCT01508936</td>\n      <td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...</td>\n      <td>Baseline (Day 1), Weeks 4, 8, 12, 16</td>\n      <td>[0.224, 0.199, 0.249, 0.152, 0.277, 0.187, 0.255, 4.8, 6.7]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>100</td>\n      <td>NCT01508936</td>\n      <td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in FEV1 Subpopula...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...</td>\n      <td>Baseline (Day 1), Week 16</td>\n      <td>[0.235, 0.179, 0.243, 0.176, 0.284, 0.234, 0.246, 0.210, 0.184]</td>\n      <td>FEV1 liters/ eosinophils 10^9/liter</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16, in, ...</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>101</td>\n      <td>NCT01508936</td>\n      <td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 4, 8, 12, and 16</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...</td>\n      <td>Baseline (Day 1), Weeks 4, 8, 12, and 16</td>\n      <td>[0.270, 0.240, 0.136, 0.256, 0.179, 0.241, -0.1, -0.2, -0.2]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, weeks, 4,, 8,,...</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>102</td>\n      <td>NCT01508936</td>\n      <td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (% Predicted FEV1...</td>\n      <td>The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a fo...</td>\n      <td>Baseline (Day 1), Weeks 4, 8, 12, and 16</td>\n      <td>[-0.3, -0.2, -0.3, -0.4, -0.3, 0.010, -0.226, 0.036, -0.239]</td>\n      <td>percentage of predicted FEV1</td>\n      <td>[change, from, baseline, in, percent, predicted, forced, expiratory, volume, in, 1, second, %, p...</td>\n    </tr>\n    <tr>\n      <th>12</th>\n      <td>116</td>\n      <td>NCT02135692</td>\n      <td>A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects</td>\n      <td>Phase 3</td>\n      <td>[Mepolizumab, SOC]</td>\n      <td>[Biological: Mepolizumab, Drug: SOC]</td>\n      <td>[Mepolizumab 100 mg, Mepolizumab 100 mg]</td>\n      <td>Secondary</td>\n      <td>Mean Change From Baseline in On-treatment Clinic Pre-bronchodilator FEV1</td>\n      <td>FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Pre-broncho...</td>\n      <td>Baseline (Week 0) to Week 168</td>\n      <td>[35, 3, 0, 1, 77, 199, 28, 0, 1.8, 0.6, 1.5, 2.0, 1.2, 1.8, 1.4]</td>\n      <td>Milliliter</td>\n      <td>[mean, change, from, baseline, in, on-treatment, clinic, pre-bronchodilator, fev1]</td>\n    </tr>\n    <tr>\n      <th>13</th>\n      <td>132</td>\n      <td>NCT02869438</td>\n      <td>A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...</td>\n      <td>Phase 3</td>\n      <td>[Benralizumab, Placebo]</td>\n      <td>[Drug: Benralizumab, Other: Placebo]</td>\n      <td>[Benralizumab arm, Placebo arm]</td>\n      <td>Primary</td>\n      <td>Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in P...</td>\n      <td>The average over the mean differences between benralizumab and placebo for change from baseline ...</td>\n      <td>From first IP dose to Day 84</td>\n      <td>[0.21, 0.132, 0.22, 0.203, 0.209]</td>\n      <td>Liter</td>\n      <td>[change, from, baseline, visit, 4, to, day, 28, visit, 8),, day, 56, visit, 9),, and, day, 84, v...</td>\n    </tr>\n    <tr>\n      <th>14</th>\n      <td>135</td>\n      <td>NCT02869438</td>\n      <td>A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...</td>\n      <td>Phase 3</td>\n      <td>[Benralizumab, Placebo]</td>\n      <td>[Drug: Benralizumab, Other: Placebo]</td>\n      <td>[Benralizumab arm, Placebo arm]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1</td>\n      <td>Post baseline visits include Day 3, Day 7, Day 14, Day 28, Day 56, Day 84. [Note: Day 28, 56, 84...</td>\n      <td>From first IP dose to Day 84</td>\n      <td>[0.1, 0.122, 0.11, 0.138, 0.099]</td>\n      <td>Liter</td>\n      <td>[change, from, baseline, visit, 4, to, post, baseline, visits, in, pre-bd, fev1]</td>\n    </tr>\n    <tr>\n      <th>15</th>\n      <td>157</td>\n      <td>NCT03170271</td>\n      <td>A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontroll...</td>\n      <td>Phase 3</td>\n      <td>[Benralizumab (Medi-563), Placebo]</td>\n      <td>[Drug: Benralizumab (Medi-563), Drug: Placebo]</td>\n      <td>[Benralizumab (Medi-563), Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in First Second (FEV1) ...</td>\n      <td>Lung function was assessed by FEV1 which was measured by spirometry. Spirometry was performed by...</td>\n      <td>Baseline (Week 0) and Week 24</td>\n      <td>[123, 107, 27.17, 7.06]</td>\n      <td>Liters (L)</td>\n      <td>[change, from, baseline, in, pre-bronchodilator, bd, forced, expiratory, volume, in, first, seco...</td>\n    </tr>\n    <tr>\n      <th>16</th>\n      <td>170</td>\n      <td>NCT01842607</td>\n      <td>A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects</td>\n      <td>Phase 3</td>\n      <td>[Mepolizumab]</td>\n      <td>[Biological: Mepolizumab]</td>\n      <td>[Mepolizumab Arm]</td>\n      <td>Secondary</td>\n      <td>Mean Change From Baseline in Clinic Pre-bronchodilator FEV1 Over the 52-week Treatment Period</td>\n      <td>FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Pre-broncho...</td>\n      <td>From Baseline and up to Week 52</td>\n      <td>[4, 0, 1, 0, 0, 0, 0, 0, 0]</td>\n      <td>Milliliters (mL)</td>\n      <td>[mean, change, from, baseline, in, clinic, pre-bronchodilator, fev1, over, the, 52-week, treatme...</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "17 individual endpoints were reported concerning change from baseline in FEV1. I note in the 'InterventionName' column that most of the approved biologic treatments available for severe/eosinophilic asthma (reslizumab, benralizumab, mepolizumab) report change from baseline in FEV1. I will use the plot_outcome_search function to plot the number of endpoints returned from this search."
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "plot_outcome_search(search_results)",
            "execution_count": 12,
            "outputs": [
                {
                    "output_type": "display_data",
                    "data": {
                        "text/plain": "<Figure size 1008x432 with 1 Axes>",
                        "image/png": "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\n"
                    },
                    "metadata": {
                        "needs_background": "light"
                    }
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "# \nI will repeat the above process using a different example - I will search for any clinical trials involving 'severe atopic dermatitis', or eczema, an inflammatory skin condition.\n# "
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "atopic_derm = Query()\natopic_derm.build_query()",
            "execution_count": 13,
            "outputs": [
                {
                    "output_type": "stream",
                    "name": "stdout",
                    "text": "\n\nEnter the search query term: \n\nsevere atopic dermatitis\n\n\nSearch Term: \n\nsevere atopic dermatitis\n\n\n\n\nQuerying up to 1,000 trials from clinicaltrials.gov with the following url...\n\nhttps://clinicaltrials.gov/api/query/study_fields?expr=severe+atopic+dermatitis&fields=NCTId%2CBriefTitle%2CCondition%2CPhase%2CStudyType%2CEnrollmentCount%2CStartDate%2CPrimaryCompletionDate%2CEligibilityCriteria%2CInterventionName%2CArmGroupInterventionName%2CArmGroupDescription%2CInterventionArmGroupLabel%2COutcomeMeasureType%2COutcomeMeasureTitle%2COutcomeMeasureDescription%2COutcomeMeasureTimeFrame%2COutcomeMeasurementValue%2COutcomeMeasureUnitOfMeasure&min_rnk=1&max_rnk=1000&fmt=json\n\n\n"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 13,
                    "data": {
                        "text/plain": "'https://clinicaltrials.gov/api/query/study_fields?expr=severe+atopic+dermatitis&fields=NCTId%2CBriefTitle%2CCondition%2CPhase%2CStudyType%2CEnrollmentCount%2CStartDate%2CPrimaryCompletionDate%2CEligibilityCriteria%2CInterventionName%2CArmGroupInterventionName%2CArmGroupDescription%2CInterventionArmGroupLabel%2COutcomeMeasureType%2COutcomeMeasureTitle%2COutcomeMeasureDescription%2COutcomeMeasureTimeFrame%2COutcomeMeasurementValue%2COutcomeMeasureUnitOfMeasure&min_rnk=1&max_rnk=1000&fmt=json'"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "ad_study_table = atopic_derm.build_study_table(atopic_derm.get_url())\nad_study_table.head(10)",
            "execution_count": 14,
            "outputs": [
                {
                    "output_type": "stream",
                    "text": "/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:52: FutureWarning: pandas.io.json.json_normalize is deprecated, use pandas.json_normalize instead\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:56: FutureWarning: pandas.io.json.json_normalize is deprecated, use pandas.json_normalize instead\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:84: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:82: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
                    "name": "stderr"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 14,
                    "data": {
                        "text/plain": "   Rank        NCTId  \\\n0    13  NCT03054428   \n1    14  NCT03831191   \n2    15  NCT03334422   \n3    16  NCT01785602   \n4    17  NCT03443024   \n5    18  NCT02002208   \n6    19  NCT03435081   \n7    20  NCT03334396   \n8    21  NCT01945086   \n9    22  NCT00832585   \n\n                                                                                            BriefTitle  \\\n0  Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n1                             A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis   \n2               Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n3  Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic ...   \n4        A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis   \n5                                           Effect of OC000459 on Moderate to Severe Atopic Dermatitis   \n6   A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis   \n7             A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n8       A Study of Ustekinumab (STELARA\u00ae) in Adult Japanese Participants With Severe Atopic Dermatitis   \n9  Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Se...   \n\n                              Condition    Phase       StudyType  \\\n0  Moderate-to-Severe Atopic Dermatitis  Phase 3  Interventional   \n1                     Atopic Dermatitis  Phase 2  Interventional   \n2                     Atopic Dermatitis  Phase 3  Interventional   \n3                     Atopic Dermatitis  Phase 2  Interventional   \n4                     Atopic Dermatitis  Phase 2  Interventional   \n5                     Atopic Dermatitis  Phase 2  Interventional   \n6                     Atopic Dermatitis  Phase 3  Interventional   \n7                     Atopic Dermatitis  Phase 3  Interventional   \n8                    Dermatitis, Atopic  Phase 2  Interventional   \n9                     Atopic Dermatitis  Phase 4  Interventional   \n\n  EnrollmentCount          StartDate PrimaryCompletionDate  \\\n0             251     March 21, 2017         April 4, 2018   \n1             136  February 12, 2019     February 27, 2020   \n2             615  November 27, 2017     December 12, 2018   \n3             103          June 2013         November 2014   \n4             280   January 30, 2018      February 7, 2019   \n5             142       October 2013        September 2015   \n6             440  February 20, 2018      December 9, 2019   \n7             660  November 23, 2017      December 6, 2018   \n8              79     September 2013         December 2014   \n9               5       January 2008        September 2009   \n\n                                                                                   EligibilityCriteria  \\\n0  Inclusion Criteria:\\n\\nMale or female \u226512 to <18 years of age at time of screening visit\\nDiagno...   \n1  Inclusion Criteria:\\n\\nParticipants must have diagnosis of AD >= 12 months according to the Amer...   \n2  Inclusion Criteria:\\n\\nHave been diagnosed with moderate to severe Atopic Dermatitis for at leas...   \n3  Key Inclusion Criteria:\\n\\nPresence of atopic dermatitis confirmed by Itchy skin condition in th...   \n4  Inclusion Criteria:\\n\\nMale or female, 18 years or older.\\nChronic AD as defined by Hanifin and ...   \n5  Inclusion Criteria:\\n\\nAtopic dermatitis as defined by a score of at least 9 on the Nottingham E...   \n6  Inclusion Criteria:\\n\\nHave a diagnosis of atopic dermatitis (AD) at least 12 months before scre...   \n7  Inclusion Criteria:\\n\\nHave been diagnosed with moderate to severe Atopic Dermatitis for at leas...   \n8  Inclusion Criteria:\\n\\nMust be Japanese\\nMust have a diagnosis of atopic dermatitis, with childh...   \n9  Inclusion Criteria:\\n\\nSigned Informed Consent Form(s)\\nAge of l8 years or older\\nA diagnosis of...   \n\n                                                                InterventionName  \\\n0                                                           [Dupilumab, Placebo]   \n1                                                           [LY3375880, Placebo]   \n2                                                         [Baricitinib, Placebo]   \n3                                                              [QAW039, Placebo]   \n4                                                        [Lebrikizumab, Placebo]   \n5                                                                     [OC000459]   \n6                                                         [Baricitinib, Placebo]   \n7                                                         [Baricitinib, Placebo]   \n8  [Ustekinumab, Placebo, Concomitant topical medications for atopic dermatitis]   \n9                                                                    [Alefacept]   \n\n                                                                              ArmGroupInterventionName  \\\n0                                                    [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n1                                   [Drug: LY3375880, Drug: LY3375880, Drug: LY3375880, Drug: Placebo]   \n2  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n3                                                                        [Drug: QAW039, Drug: Placebo]   \n4  [Biological: Lebrikizumab, Drug: Placebo, Biological: Lebrikizumab, Drug: Placebo, Biological: L...   \n5                                                                     [Drug: OC000459, Drug: OC000459]   \n6                  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Placebo]   \n7  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n8  [Drug: Ustekinumab, Other: Concomitant topical medications for atopic dermatitis, Drug: Ustekinu...   \n9                                                                                    [Drug: Alefacept]   \n\n                                                                                   ArmGroupDescription  \\\n0  [Participants received placebo matching dupilumab once every 2 weeks (Q2W) (including doubling t...   \n1  [Induction Period:\\n\\nParticipants received 50 mg LY3375880 administered SC Q4W., Induction Peri...   \n2  [4mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every...   \n3  [Participants received QAW039 450 mg daily by mouth., Participants received matching placebo to ...   \n4  [125 mg Lebrikizumab administered subcutaneously (SC) once Q4W.\\n\\nBaseline: Loading dose 250 mg...   \n5                                                         [50 mg orally once a day, Orally once a day]   \n6  [2 mg Baricitinib administered orally every day. Placebo administered orally to maintain the bli...   \n7  [4 mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally ever...   \n8                                                                                                   []   \n9  [Amevive\u00ae has been shown to be a safe and effective agent in the treatment of psoriasis but may ...   \n\n                                                                             InterventionArmGroupLabel  \\\n0                                      [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n1                                       [150 mg LY3375880, 50 mg LY3375880, 600 mg LY3375880, Placebo]   \n2  [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n3                                                                                    [QAW039, Placebo]   \n4  [125 milligrams (mg) Lebrikizumab - Every 4 Weeks (Q4W), 250 mg Lebrikizumab - Every 2 Weeks (Q2...   \n5                                                                  [OC000459 Tablets, Placebo Tablets]   \n6  [1 mg Baricitinib, 2 milligram (mg) Baricitinib, 1 mg Baricitinib, 2 milligram (mg) Baricitinib,...   \n7  [1 mg Baricitinib, 1 mg Baricitinib Maximum Extended Enrollment Cohort, 2 mg Baricitinib, 2 mg B...   \n8       [Ustekinumab 45 mg, Ustekinumab 90 mg, Placebo, Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg]   \n9                                                                                          [Alefacept]   \n\n                                                                                    OutcomeMeasureType  \\\n0  [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n1               [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n2  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n3                                                                                 [Primary, Secondary]   \n4  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n5                                                                                 [Primary, Secondary]   \n6  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n7  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n8  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n9                                                                                 [Primary, Secondary]   \n\n                                                                                   OutcomeMeasureTitle  \\\n0  [Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction Fr...   \n1  [Percentage of Participants Achieving Validated Investigator's Global Assessment for AD (vIGA-AD...   \n2  [Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 ...   \n3  [Change From Baseline in Eczema Area and Severity Index (EASI), Change From Baseline in Eczema A...   \n4  [Percent Change From Baseline in Eczema Area and Severity Index (EASI), Percentage of Participan...   \n5  [Change From Baseline in Eczema Area and Severity Index (EASI) Compared to Placebo at Week 16, R...   \n6  [Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (2 mg Baricitin...   \n7  [Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 ...   \n8  [Percent Change in Eczema Area Severity Index (EASI) Total Score From Baseline at Week 12, Numbe...   \n9  [Change in Eczema Area Severity Index (EASI) Score From Baseline (Week 1) to Week 16., Change in...   \n\n                                                                             OutcomeMeasureDescription  \\\n0  [IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical re...   \n1  [vIGA-AD measures participants' overall severity of their atopic dermatitis (AD), based on a sta...   \n2  [The IGA measures the investigator's global assessment of the participants overall severity of t...   \n3  [Investigators assessed presence and severity of erythema, induration/papulation, excoriation, a...   \n4  [The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease ...   \n5  [The EASI scoring system uses a defined process to grade the severity of the signs of eczema and...   \n6  [The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease ...   \n7  [The IGA measures the investigator's global assessment of the participant's overall severity of ...   \n8  [The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measur...   \n9  [The Eczema Area Severity Index (EASI) measures erythema (E), infiltration (I), excoriation (Ex)...   \n\n                                                                               OutcomeMeasureTimeFrame  \\\n0  [Baseline and Week 16, Baseline and Week 16, Baseline and Week 16, Baseline and Week 16, Baselin...   \n1  [Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Baseline, Week 16, Week 52, Induction Pe...   \n2  [16 Weeks, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 We...   \n3                                                     [Baseline, 12 weeks, Baseline, 4 weeks, 8 weeks]   \n4  [Baseline, Week 16, Week 16, Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Baseline, We...   \n5                   [EASI was measured at baseline (week 0) and 16 weeks after dosing., over 16 weeks]   \n6  [Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Week 16, 16 Weeks, Baseline, Week 16, Ba...   \n7  [16 Weeks, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 We...   \n8  [Baseline and Week 12, Week 12, Baseline and Week 12, Baseline and Week 12, Week 2, 4, 8, 12, 16...   \n9                                                               [Week 1 to week 16, Week 1 to week 16]   \n\n                                                                               OutcomeMeasurementValue  \\\n0  [2.4, 17.9, 24.4, 8.2, 38.1, 41.5, -23.6, -64.8, -65.9, -19.0, -45.5, -47.9, 9.4, 38.6, 48.8, 4....   \n1  [9.5, 5.0, 5.9, 4.8, 19.0, 15.0, 23.5, 0.0, 4.8, 5.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, -11.45, -4.9...   \n2  [4.5, 10.6, 13.8, 4.5, 8.8, 6.1, 12.8, 17.9, 21.1, 2.5, 6.4, 8.9, 13.0, -28.91, -41.68, -54.80, ...   \n3                                                           [-8.65, -6.95, -6.22, -5.89, -7.49, -5.61]   \n4  [-62.34, -69.21, -72.09, -41.12, 43.3, 56.1, 60.6, 24.3, 26.6, 33.7, 44.6, 15.3, 42.2, 61.2, 61....   \n5                                                                           [-3.8, -6.1, 2.879, 2.646]   \n6  [8.2, 29.5, 5.4, 12.9, 24.0, 8.2, 12.9, 3.4, 7.5, 20.5, -34.07, -46.66, -54.37, 2.7, 3.4, 14.4, ...   \n7  [4.8, 11.4, 16.8, 4.8, 11.8, 8.8, 17.3, 18.7, 24.8, 4.8, 8.7, 10.6, 16.0, -34.82, -48.22, -51.89...   \n8  [-37.54, -38.62, -39.39, 0, 0, 0, 8.97, 10.03, 8.71, -1.58, -1.68, -2.59, 10.43, 11.22, 9.45, -2...   \n9                                                                                            [26.4, 1]   \n\n                                                                           OutcomeMeasureUnitOfMeasure  \n0  [Percentage of participants, Percentage of participants, Percent change, Percent change, Percent...  \n1  [Percentage of participants, Percentage of Participants, Percentage of participants, Percentage ...  \n2  [percentage of participants, percentage of participants, percentage of participants, percentage ...  \n3                                                                 [Score on a scale, Score on a scale]  \n4  [percent change, percentage of participants, percentage of participants, percentage of participa...  \n5                                                                           [units on a scale, flares]  \n6  [percentage of participants, percentage of participants, percentage of participants, percentage ...  \n7  [percentage of participants, percentage of participants, percentage of participants, percentage ...  \n8  [percent change, participants, units on a scale, units on a scale, participants, participants, p...  \n9                                                              [Scores on a scale., Scores on a scale]  ",
                        "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Rank</th>\n      <th>NCTId</th>\n      <th>BriefTitle</th>\n      <th>Condition</th>\n      <th>Phase</th>\n      <th>StudyType</th>\n      <th>EnrollmentCount</th>\n      <th>StartDate</th>\n      <th>PrimaryCompletionDate</th>\n      <th>EligibilityCriteria</th>\n      <th>InterventionName</th>\n      <th>ArmGroupInterventionName</th>\n      <th>ArmGroupDescription</th>\n      <th>InterventionArmGroupLabel</th>\n      <th>OutcomeMeasureType</th>\n      <th>OutcomeMeasureTitle</th>\n      <th>OutcomeMeasureDescription</th>\n      <th>OutcomeMeasureTimeFrame</th>\n      <th>OutcomeMeasurementValue</th>\n      <th>OutcomeMeasureUnitOfMeasure</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>13</td>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Moderate-to-Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>251</td>\n      <td>March 21, 2017</td>\n      <td>April 4, 2018</td>\n      <td>Inclusion Criteria:\\n\\nMale or female \u226512 to &lt;18 years of age at time of screening visit\\nDiagno...</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Participants received placebo matching dupilumab once every 2 weeks (Q2W) (including doubling t...</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction Fr...</td>\n      <td>[IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical re...</td>\n      <td>[Baseline and Week 16, Baseline and Week 16, Baseline and Week 16, Baseline and Week 16, Baselin...</td>\n      <td>[2.4, 17.9, 24.4, 8.2, 38.1, 41.5, -23.6, -64.8, -65.9, -19.0, -45.5, -47.9, 9.4, 38.6, 48.8, 4....</td>\n      <td>[Percentage of participants, Percentage of participants, Percent change, Percent change, Percent...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>14</td>\n      <td>NCT03831191</td>\n      <td>A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>136</td>\n      <td>February 12, 2019</td>\n      <td>February 27, 2020</td>\n      <td>Inclusion Criteria:\\n\\nParticipants must have diagnosis of AD &gt;= 12 months according to the Amer...</td>\n      <td>[LY3375880, Placebo]</td>\n      <td>[Drug: LY3375880, Drug: LY3375880, Drug: LY3375880, Drug: Placebo]</td>\n      <td>[Induction Period:\\n\\nParticipants received 50 mg LY3375880 administered SC Q4W., Induction Peri...</td>\n      <td>[150 mg LY3375880, 50 mg LY3375880, 600 mg LY3375880, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Percentage of Participants Achieving Validated Investigator's Global Assessment for AD (vIGA-AD...</td>\n      <td>[vIGA-AD measures participants' overall severity of their atopic dermatitis (AD), based on a sta...</td>\n      <td>[Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Baseline, Week 16, Week 52, Induction Pe...</td>\n      <td>[9.5, 5.0, 5.9, 4.8, 19.0, 15.0, 23.5, 0.0, 4.8, 5.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, -11.45, -4.9...</td>\n      <td>[Percentage of participants, Percentage of Participants, Percentage of participants, Percentage ...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>15</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>615</td>\n      <td>November 27, 2017</td>\n      <td>December 12, 2018</td>\n      <td>Inclusion Criteria:\\n\\nHave been diagnosed with moderate to severe Atopic Dermatitis for at leas...</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[4mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 ...</td>\n      <td>[The IGA measures the investigator's global assessment of the participants overall severity of t...</td>\n      <td>[16 Weeks, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 We...</td>\n      <td>[4.5, 10.6, 13.8, 4.5, 8.8, 6.1, 12.8, 17.9, 21.1, 2.5, 6.4, 8.9, 13.0, -28.91, -41.68, -54.80, ...</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, percentage ...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>16</td>\n      <td>NCT01785602</td>\n      <td>Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic ...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>103</td>\n      <td>June 2013</td>\n      <td>November 2014</td>\n      <td>Key Inclusion Criteria:\\n\\nPresence of atopic dermatitis confirmed by Itchy skin condition in th...</td>\n      <td>[QAW039, Placebo]</td>\n      <td>[Drug: QAW039, Drug: Placebo]</td>\n      <td>[Participants received QAW039 450 mg daily by mouth., Participants received matching placebo to ...</td>\n      <td>[QAW039, Placebo]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Change From Baseline in Eczema Area and Severity Index (EASI), Change From Baseline in Eczema A...</td>\n      <td>[Investigators assessed presence and severity of erythema, induration/papulation, excoriation, a...</td>\n      <td>[Baseline, 12 weeks, Baseline, 4 weeks, 8 weeks]</td>\n      <td>[-8.65, -6.95, -6.22, -5.89, -7.49, -5.61]</td>\n      <td>[Score on a scale, Score on a scale]</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>17</td>\n      <td>NCT03443024</td>\n      <td>A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>280</td>\n      <td>January 30, 2018</td>\n      <td>February 7, 2019</td>\n      <td>Inclusion Criteria:\\n\\nMale or female, 18 years or older.\\nChronic AD as defined by Hanifin and ...</td>\n      <td>[Lebrikizumab, Placebo]</td>\n      <td>[Biological: Lebrikizumab, Drug: Placebo, Biological: Lebrikizumab, Drug: Placebo, Biological: L...</td>\n      <td>[125 mg Lebrikizumab administered subcutaneously (SC) once Q4W.\\n\\nBaseline: Loading dose 250 mg...</td>\n      <td>[125 milligrams (mg) Lebrikizumab - Every 4 Weeks (Q4W), 250 mg Lebrikizumab - Every 2 Weeks (Q2...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percent Change From Baseline in Eczema Area and Severity Index (EASI), Percentage of Participan...</td>\n      <td>[The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease ...</td>\n      <td>[Baseline, Week 16, Week 16, Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Baseline, We...</td>\n      <td>[-62.34, -69.21, -72.09, -41.12, 43.3, 56.1, 60.6, 24.3, 26.6, 33.7, 44.6, 15.3, 42.2, 61.2, 61....</td>\n      <td>[percent change, percentage of participants, percentage of participants, percentage of participa...</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>18</td>\n      <td>NCT02002208</td>\n      <td>Effect of OC000459 on Moderate to Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>142</td>\n      <td>October 2013</td>\n      <td>September 2015</td>\n      <td>Inclusion Criteria:\\n\\nAtopic dermatitis as defined by a score of at least 9 on the Nottingham E...</td>\n      <td>[OC000459]</td>\n      <td>[Drug: OC000459, Drug: OC000459]</td>\n      <td>[50 mg orally once a day, Orally once a day]</td>\n      <td>[OC000459 Tablets, Placebo Tablets]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Change From Baseline in Eczema Area and Severity Index (EASI) Compared to Placebo at Week 16, R...</td>\n      <td>[The EASI scoring system uses a defined process to grade the severity of the signs of eczema and...</td>\n      <td>[EASI was measured at baseline (week 0) and 16 weeks after dosing., over 16 weeks]</td>\n      <td>[-3.8, -6.1, 2.879, 2.646]</td>\n      <td>[units on a scale, flares]</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>19</td>\n      <td>NCT03435081</td>\n      <td>A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>440</td>\n      <td>February 20, 2018</td>\n      <td>December 9, 2019</td>\n      <td>Inclusion Criteria:\\n\\nHave a diagnosis of atopic dermatitis (AD) at least 12 months before scre...</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Placebo]</td>\n      <td>[2 mg Baricitinib administered orally every day. Placebo administered orally to maintain the bli...</td>\n      <td>[1 mg Baricitinib, 2 milligram (mg) Baricitinib, 1 mg Baricitinib, 2 milligram (mg) Baricitinib,...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (2 mg Baricitin...</td>\n      <td>[The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease ...</td>\n      <td>[Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Week 16, 16 Weeks, Baseline, Week 16, Ba...</td>\n      <td>[8.2, 29.5, 5.4, 12.9, 24.0, 8.2, 12.9, 3.4, 7.5, 20.5, -34.07, -46.66, -54.37, 2.7, 3.4, 14.4, ...</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, percentage ...</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>20</td>\n      <td>NCT03334396</td>\n      <td>A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>660</td>\n      <td>November 23, 2017</td>\n      <td>December 6, 2018</td>\n      <td>Inclusion Criteria:\\n\\nHave been diagnosed with moderate to severe Atopic Dermatitis for at leas...</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[4 mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally ever...</td>\n      <td>[1 mg Baricitinib, 1 mg Baricitinib Maximum Extended Enrollment Cohort, 2 mg Baricitinib, 2 mg B...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 ...</td>\n      <td>[The IGA measures the investigator's global assessment of the participant's overall severity of ...</td>\n      <td>[16 Weeks, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 We...</td>\n      <td>[4.8, 11.4, 16.8, 4.8, 11.8, 8.8, 17.3, 18.7, 24.8, 4.8, 8.7, 10.6, 16.0, -34.82, -48.22, -51.89...</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, percentage ...</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>21</td>\n      <td>NCT01945086</td>\n      <td>A Study of Ustekinumab (STELARA\u00ae) in Adult Japanese Participants With Severe Atopic Dermatitis</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>79</td>\n      <td>September 2013</td>\n      <td>December 2014</td>\n      <td>Inclusion Criteria:\\n\\nMust be Japanese\\nMust have a diagnosis of atopic dermatitis, with childh...</td>\n      <td>[Ustekinumab, Placebo, Concomitant topical medications for atopic dermatitis]</td>\n      <td>[Drug: Ustekinumab, Other: Concomitant topical medications for atopic dermatitis, Drug: Ustekinu...</td>\n      <td>[]</td>\n      <td>[Ustekinumab 45 mg, Ustekinumab 90 mg, Placebo, Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percent Change in Eczema Area Severity Index (EASI) Total Score From Baseline at Week 12, Numbe...</td>\n      <td>[The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measur...</td>\n      <td>[Baseline and Week 12, Week 12, Baseline and Week 12, Baseline and Week 12, Week 2, 4, 8, 12, 16...</td>\n      <td>[-37.54, -38.62, -39.39, 0, 0, 0, 8.97, 10.03, 8.71, -1.58, -1.68, -2.59, 10.43, 11.22, 9.45, -2...</td>\n      <td>[percent change, participants, units on a scale, units on a scale, participants, participants, p...</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>22</td>\n      <td>NCT00832585</td>\n      <td>Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Se...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>5</td>\n      <td>January 2008</td>\n      <td>September 2009</td>\n      <td>Inclusion Criteria:\\n\\nSigned Informed Consent Form(s)\\nAge of l8 years or older\\nA diagnosis of...</td>\n      <td>[Alefacept]</td>\n      <td>[Drug: Alefacept]</td>\n      <td>[Amevive\u00ae has been shown to be a safe and effective agent in the treatment of psoriasis but may ...</td>\n      <td>[Alefacept]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Change in Eczema Area Severity Index (EASI) Score From Baseline (Week 1) to Week 16., Change in...</td>\n      <td>[The Eczema Area Severity Index (EASI) measures erythema (E), infiltration (I), excoriation (Ex)...</td>\n      <td>[Week 1 to week 16, Week 1 to week 16]</td>\n      <td>[26.4, 1]</td>\n      <td>[Scores on a scale., Scores on a scale]</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {
                "scrolled": false
            },
            "cell_type": "code",
            "source": "ad_outcome_table = atopic_derm.build_outcome_table()\nad_outcome_table.shape",
            "execution_count": 15,
            "outputs": [
                {
                    "output_type": "execute_result",
                    "execution_count": 15,
                    "data": {
                        "text/plain": "(652, 12)"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "tokenize_column(ad_outcome_table, 'OutcomeMeasureTitle', 'OutcomeMeasureTitleTokenized')",
            "execution_count": 16,
            "outputs": []
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "print(ad_outcome_table.shape)\nad_outcome_table.head()",
            "execution_count": 17,
            "outputs": [
                {
                    "output_type": "stream",
                    "text": "(652, 13)\n",
                    "name": "stdout"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 17,
                    "data": {
                        "text/plain": "         NCTId  \\\n0  NCT03054428   \n1  NCT03054428   \n2  NCT03054428   \n3  NCT03054428   \n4  NCT03054428   \n\n                                                                                            BriefTitle  \\\n0  Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n1  Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n2  Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n3  Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n4  Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n\n     Phase      InterventionName  \\\n0  Phase 3  [Dupilumab, Placebo]   \n1  Phase 3  [Dupilumab, Placebo]   \n2  Phase 3  [Dupilumab, Placebo]   \n3  Phase 3  [Dupilumab, Placebo]   \n4  Phase 3  [Dupilumab, Placebo]   \n\n                            ArmGroupInterventionName  \\\n0  [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n1  [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n2  [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n3  [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n4  [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n\n                                         InterventionArmGroupLabel  \\\n0  [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n1  [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n2  [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n3  [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n4  [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n\n  OutcomeMeasureType  \\\n0            Primary   \n1            Primary   \n2          Secondary   \n3          Secondary   \n4          Secondary   \n\n                                                                                   OutcomeMeasureTitle  \\\n0  Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction Fro...   \n1  Percentage of Participants With Eczema Area and Severity Index (EASI)-75 (\u226575% Improvement From ...   \n2                                                Percent Change From Baseline in EASI Score at Week 16   \n3  Percent Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NR...   \n4  Percentage of Participants With Improvement (Reduction \u22653 Points) of Weekly Average of Daily Pea...   \n\n                                                                             OutcomeMeasureDescription  \\\n0  IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical res...   \n1  The EASI score was used to measure the severity and extent of AD and measures erythema, infiltra...   \n2  The Eczema Area and Severity Index (EASI) score was used to measure the severity and extent of A...   \n3  Peak Pruritus NRS is an assessment tool used by subjects to report intensity of pruritus (itch) ...   \n4  Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (it...   \n\n  OutcomeMeasureTimeFrame OutcomeMeasurementValue OutcomeMeasureUnitOfMeasure  \\\n0    Baseline and Week 16       [2.4, 17.9, 24.4]  Percentage of participants   \n1    Baseline and Week 16       [8.2, 38.1, 41.5]  Percentage of participants   \n2    Baseline and Week 16   [-23.6, -64.8, -65.9]              Percent change   \n3    Baseline and Week 16   [-19.0, -45.5, -47.9]              Percent change   \n4     Baseline to Week 16       [9.4, 38.6, 48.8]  Percentage of participants   \n\n                                                                          OutcomeMeasureTitleTokenized  \n0  [percentage, of, participants, with, investigator's, global, assessment, iga, 0, or, 1, and, red...  \n1  [percentage, of, participants, with, eczema, area, and, severity, index, easi)-75, \u226575%, improve...  \n2                                     [percent, change, from, baseline, in, easi, score, at, week, 16]  \n3  [percent, change, from, baseline, in, weekly, average, of, daily, peak, pruritus, numerical, rat...  \n4  [percentage, of, participants, with, improvement, reduction, \u22653, points, of, weekly, average, of...  ",
                        "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>NCTId</th>\n      <th>BriefTitle</th>\n      <th>Phase</th>\n      <th>InterventionName</th>\n      <th>ArmGroupInterventionName</th>\n      <th>InterventionArmGroupLabel</th>\n      <th>OutcomeMeasureType</th>\n      <th>OutcomeMeasureTitle</th>\n      <th>OutcomeMeasureDescription</th>\n      <th>OutcomeMeasureTimeFrame</th>\n      <th>OutcomeMeasurementValue</th>\n      <th>OutcomeMeasureUnitOfMeasure</th>\n      <th>OutcomeMeasureTitleTokenized</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>Primary</td>\n      <td>Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction Fro...</td>\n      <td>IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical res...</td>\n      <td>Baseline and Week 16</td>\n      <td>[2.4, 17.9, 24.4]</td>\n      <td>Percentage of participants</td>\n      <td>[percentage, of, participants, with, investigator's, global, assessment, iga, 0, or, 1, and, red...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>Primary</td>\n      <td>Percentage of Participants With Eczema Area and Severity Index (EASI)-75 (\u226575% Improvement From ...</td>\n      <td>The EASI score was used to measure the severity and extent of AD and measures erythema, infiltra...</td>\n      <td>Baseline and Week 16</td>\n      <td>[8.2, 38.1, 41.5]</td>\n      <td>Percentage of participants</td>\n      <td>[percentage, of, participants, with, eczema, area, and, severity, index, easi)-75, \u226575%, improve...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>Secondary</td>\n      <td>Percent Change From Baseline in EASI Score at Week 16</td>\n      <td>The Eczema Area and Severity Index (EASI) score was used to measure the severity and extent of A...</td>\n      <td>Baseline and Week 16</td>\n      <td>[-23.6, -64.8, -65.9]</td>\n      <td>Percent change</td>\n      <td>[percent, change, from, baseline, in, easi, score, at, week, 16]</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>Secondary</td>\n      <td>Percent Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NR...</td>\n      <td>Peak Pruritus NRS is an assessment tool used by subjects to report intensity of pruritus (itch) ...</td>\n      <td>Baseline and Week 16</td>\n      <td>[-19.0, -45.5, -47.9]</td>\n      <td>Percent change</td>\n      <td>[percent, change, from, baseline, in, weekly, average, of, daily, peak, pruritus, numerical, rat...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants With Improvement (Reduction \u22653 Points) of Weekly Average of Daily Pea...</td>\n      <td>Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (it...</td>\n      <td>Baseline to Week 16</td>\n      <td>[9.4, 38.6, 48.8]</td>\n      <td>Percentage of participants</td>\n      <td>[percentage, of, participants, with, improvement, reduction, \u22653, points, of, weekly, average, of...</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {
                "scrolled": false
            },
            "cell_type": "code",
            "source": "search_results_ad = search_outcomes(ad_outcome_table, 'OutcomeMeasureTitleTokenized')\nsearch_results_ad.head(10)",
            "execution_count": 21,
            "outputs": [
                {
                    "output_type": "stream",
                    "name": "stdout",
                    "text": "Enter your search term here: \nIGA 0 1\n\nSearching outcomes that contain the following key terms:\n\n['iga', '0', '1']\n"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 21,
                    "data": {
                        "text/plain": "   index        NCTId  \\\n0      0  NCT03054428   \n1     20  NCT03334422   \n2     21  NCT03334422   \n3     43  NCT03334422   \n4     44  NCT03334422   \n5     45  NCT03334422   \n6     67  NCT03334422   \n7     69  NCT03435081   \n8     91  NCT03435081   \n9     92  NCT03334396   \n\n                                                                                            BriefTitle  \\\n0  Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n1               Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n2               Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n3               Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n4               Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n5               Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n6               Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n7   A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis   \n8   A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis   \n9             A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n\n     Phase        InterventionName  \\\n0  Phase 3    [Dupilumab, Placebo]   \n1  Phase 3  [Baricitinib, Placebo]   \n2  Phase 3  [Baricitinib, Placebo]   \n3  Phase 3  [Baricitinib, Placebo]   \n4  Phase 3  [Baricitinib, Placebo]   \n5  Phase 3  [Baricitinib, Placebo]   \n6  Phase 3  [Baricitinib, Placebo]   \n7  Phase 3  [Baricitinib, Placebo]   \n8  Phase 3  [Baricitinib, Placebo]   \n9  Phase 3  [Baricitinib, Placebo]   \n\n                                                                              ArmGroupInterventionName  \\\n0                                                    [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n1  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n2  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n3  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n4  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n5  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n6  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n7                  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Placebo]   \n8                  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Placebo]   \n9  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n\n                                                                             InterventionArmGroupLabel  \\\n0                                      [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n1  [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n2  [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n3  [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n4  [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n5  [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n6  [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n7  [1 mg Baricitinib, 2 milligram (mg) Baricitinib, 1 mg Baricitinib, 2 milligram (mg) Baricitinib,...   \n8  [1 mg Baricitinib, 2 milligram (mg) Baricitinib, 1 mg Baricitinib, 2 milligram (mg) Baricitinib,...   \n9  [1 mg Baricitinib, 1 mg Baricitinib Maximum Extended Enrollment Cohort, 2 mg Baricitinib, 2 mg B...   \n\n  OutcomeMeasureType  \\\n0            Primary   \n1            Primary   \n2          Secondary   \n3          Secondary   \n4            Primary   \n5          Secondary   \n6          Secondary   \n7          Secondary   \n8          Secondary   \n9            Primary   \n\n                                                                                   OutcomeMeasureTitle  \\\n0  Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction Fro...   \n1  Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n2  Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement (Placebo, 1mg Ba...   \n3  Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n4  Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n5  Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement (Placebo, 1mg Ba...   \n6  Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n7  Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n8  Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n9  Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n\n                                                                             OutcomeMeasureDescription  \\\n0  IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical res...   \n1  The IGA measures the investigator's global assessment of the participants overall severity of th...   \n2  The IGA measures the investigator's global assessment of the participants overall severity of th...   \n3  The IGA measures the investigator's global assessment of the participants overall severity of th...   \n4  The IGA measures the investigator's global assessment of the participants overall severity of th...   \n5  The IGA measures the investigator's global assessment of the participants overall severity of th...   \n6  The IGA measures the investigator's global assessment of the participants overall severity of th...   \n7  The IGA measures the investigator's global assessment of the participant's overall severity of t...   \n8  The IGA measures the investigator's global assessment of the participant's overall severity of t...   \n9  The IGA measures the investigator's global assessment of the participant's overall severity of t...   \n\n  OutcomeMeasureTimeFrame          OutcomeMeasurementValue  \\\n0    Baseline and Week 16                [2.4, 17.9, 24.4]   \n1                16 Weeks           [4.5, 10.6, 13.8, 4.5]   \n2                16 Weeks           [8.8, 6.1, 12.8, 17.9]   \n3                 4 Weeks  [-16.28, -8.94, -11.21, -23.25]   \n4                16 Weeks           [4.5, 10.6, 13.8, 4.5]   \n5                16 Weeks           [8.8, 6.1, 12.8, 17.9]   \n6                 4 Weeks  [-16.28, -8.94, -11.21, -23.25]   \n7                 Week 16                [12.9, 24.0, 8.2]   \n8                  Week 4          [-17.15, -9.24, -18.87]   \n9                16 Weeks           [4.8, 11.4, 16.8, 4.8]   \n\n  OutcomeMeasureUnitOfMeasure  \\\n0  Percentage of participants   \n1  percentage of participants   \n2  percentage of participants   \n3  percentage of participants   \n4  percentage of participants   \n5  percentage of participants   \n6  percentage of participants   \n7  percentage of participants   \n8  percentage of participants   \n9  percentage of participants   \n\n                                                                          OutcomeMeasureTitleTokenized  \n0  [percentage, of, participants, with, investigator's, global, assessment, iga, 0, or, 1, and, red...  \n1  [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n2  [percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement, ...  \n3  [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n4  [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n5  [percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement, ...  \n6  [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n7  [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n8  [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n9  [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  ",
                        "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>index</th>\n      <th>NCTId</th>\n      <th>BriefTitle</th>\n      <th>Phase</th>\n      <th>InterventionName</th>\n      <th>ArmGroupInterventionName</th>\n      <th>InterventionArmGroupLabel</th>\n      <th>OutcomeMeasureType</th>\n      <th>OutcomeMeasureTitle</th>\n      <th>OutcomeMeasureDescription</th>\n      <th>OutcomeMeasureTimeFrame</th>\n      <th>OutcomeMeasurementValue</th>\n      <th>OutcomeMeasureUnitOfMeasure</th>\n      <th>OutcomeMeasureTitleTokenized</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>0</td>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>Primary</td>\n      <td>Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction Fro...</td>\n      <td>IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical res...</td>\n      <td>Baseline and Week 16</td>\n      <td>[2.4, 17.9, 24.4]</td>\n      <td>Percentage of participants</td>\n      <td>[percentage, of, participants, with, investigator's, global, assessment, iga, 0, or, 1, and, red...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>20</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>Primary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participants overall severity of th...</td>\n      <td>16 Weeks</td>\n      <td>[4.5, 10.6, 13.8, 4.5]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>21</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement (Placebo, 1mg Ba...</td>\n      <td>The IGA measures the investigator's global assessment of the participants overall severity of th...</td>\n      <td>16 Weeks</td>\n      <td>[8.8, 6.1, 12.8, 17.9]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement, ...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>43</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participants overall severity of th...</td>\n      <td>4 Weeks</td>\n      <td>[-16.28, -8.94, -11.21, -23.25]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>44</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>Primary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participants overall severity of th...</td>\n      <td>16 Weeks</td>\n      <td>[4.5, 10.6, 13.8, 4.5]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>45</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement (Placebo, 1mg Ba...</td>\n      <td>The IGA measures the investigator's global assessment of the participants overall severity of th...</td>\n      <td>16 Weeks</td>\n      <td>[8.8, 6.1, 12.8, 17.9]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement, ...</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>67</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participants overall severity of th...</td>\n      <td>4 Weeks</td>\n      <td>[-16.28, -8.94, -11.21, -23.25]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>69</td>\n      <td>NCT03435081</td>\n      <td>A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Placebo]</td>\n      <td>[1 mg Baricitinib, 2 milligram (mg) Baricitinib, 1 mg Baricitinib, 2 milligram (mg) Baricitinib,...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participant's overall severity of t...</td>\n      <td>Week 16</td>\n      <td>[12.9, 24.0, 8.2]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>91</td>\n      <td>NCT03435081</td>\n      <td>A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Placebo]</td>\n      <td>[1 mg Baricitinib, 2 milligram (mg) Baricitinib, 1 mg Baricitinib, 2 milligram (mg) Baricitinib,...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participant's overall severity of t...</td>\n      <td>Week 4</td>\n      <td>[-17.15, -9.24, -18.87]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>92</td>\n      <td>NCT03334396</td>\n      <td>A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1 mg Baricitinib, 1 mg Baricitinib Maximum Extended Enrollment Cohort, 2 mg Baricitinib, 2 mg B...</td>\n      <td>Primary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participant's overall severity of t...</td>\n      <td>16 Weeks</td>\n      <td>[4.8, 11.4, 16.8, 4.8]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {
                "scrolled": false
            },
            "cell_type": "code",
            "source": "plot_outcome_search(search_results_ad)",
            "execution_count": 19,
            "outputs": [
                {
                    "output_type": "display_data",
                    "data": {
                        "text/plain": "<Figure size 1008x432 with 1 Axes>",
                        "image/png": "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\n"
                    },
                    "metadata": {
                        "needs_background": "light"
                    }
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "For future iterations of this project, I will determine a method to reconcile endpoints that were reported inconsistently (variations in spelling / grammar / word choice, but pertaining to the same outcome measure) to be able to chart which endpoints were reported most/least frequently across the clinical trials within the Query.\n\nThe example below represents the type of functionality I intend to add to this tool in future iterations."
        },
        {
            "metadata": {
                "scrolled": false
            },
            "cell_type": "code",
            "source": "query1 = Query()\nquery1.build_query()\n\nstudy_table = query1.build_study_table(query1.get_url())\noutcome_table = query1.build_outcome_table()\noutcome_table_primary = outcome_table[outcome_table['OutcomeMeasureType'].str.match('.*[Pp]rimary.*')]\n\noutcome_tracker = {}\noutcome_track(outcome_table_primary['OutcomeMeasureTitle'], outcome_tracker)\noutcome_tracker_df = pd.Series(outcome_tracker).to_frame('Frequency').reset_index().sort_values(by='Frequency', ascending=False).reset_index().drop(columns='level_0')\n\nplot_outcomes(outcome_tracker_df, query1)",
            "execution_count": 20,
            "outputs": [
                {
                    "output_type": "stream",
                    "name": "stdout",
                    "text": "\n\nEnter the search query term: \n\nsevere atopic dermatitis\n\n\nSearch Term: \n\nsevere atopic dermatitis\n\n\n\n\nQuerying up to 1,000 trials from clinicaltrials.gov with the following url...\n\nhttps://clinicaltrials.gov/api/query/study_fields?expr=severe+atopic+dermatitis&fields=NCTId%2CBriefTitle%2CCondition%2CPhase%2CStudyType%2CEnrollmentCount%2CStartDate%2CPrimaryCompletionDate%2CEligibilityCriteria%2CInterventionName%2CArmGroupInterventionName%2CArmGroupDescription%2CInterventionArmGroupLabel%2COutcomeMeasureType%2COutcomeMeasureTitle%2COutcomeMeasureDescription%2COutcomeMeasureTimeFrame%2COutcomeMeasurementValue%2COutcomeMeasureUnitOfMeasure&min_rnk=1&max_rnk=1000&fmt=json\n\n\n"
                },
                {
                    "output_type": "stream",
                    "text": "/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:52: FutureWarning: pandas.io.json.json_normalize is deprecated, use pandas.json_normalize instead\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:56: FutureWarning: pandas.io.json.json_normalize is deprecated, use pandas.json_normalize instead\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:84: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:82: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
                    "name": "stderr"
                },
                {
                    "output_type": "display_data",
                    "data": {
                        "text/plain": "<Figure size 2592x720 with 1 Axes>",
                        "image/png": "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\n"
                    },
                    "metadata": {
                        "needs_background": "light"
                    }
                }
            ]
        }
    ],
    "metadata": {
        "kernelspec": {
            "name": "python3",
            "display_name": "Python 3.7",
            "language": "python"
        },
        "language_info": {
            "name": "python",
            "version": "3.7.10",
            "mimetype": "text/x-python",
            "codemirror_mode": {
                "name": "ipython",
                "version": 3
            },
            "pygments_lexer": "ipython3",
            "nbconvert_exporter": "python",
            "file_extension": ".py"
        },
        "metadata": {
            "interpreter": {
                "hash": "59a4d4b4478b5f20e331a2a4cc8c12e2d26aa12bbd9e314e40fe03f165a80710"
            }
        }
    },
    "nbformat": 4,
    "nbformat_minor": 5
}